СПИСОК ЛИТЕРАТУРЫ
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И. И. Дедов, М. В. Шестакова // Сахарный диабет. -
2011. -№3. -Прил. 1. - С. 4-72.
2.
Аметов, А. С. Уровень гликированного гемоглобина как значимый маркер полноценного гликемического контроля и предиктор поздних сосудистых осложнений сахарного диабета 2 типа / А. С. Аметов // Русский мед. жури. -2011. -Т. 19.-№13.-С. 832-837.3. Аронов, Д. М. Каскад терапевтических эффектов статинов / Д. М. Аронов // Кардиология. - 2004. - №10. - С. 85-94.
4. Арутюнов, Г. П. Коронарный атеросклероз. Новые данные для нового взгляда на вечную проблему / Г. П. Арутюнов // Сердце. - 2005. - Т. 4. - № 1. - С. 4-10.
5. Ахмедов, В. А. Особенности иммунологических нарушений у больных инфарктом миокарда / В. А. Ахмедов, А. С. Тращенко, Т. Ф. Соколова // Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. - 2009. - Т. 7. - № 3. - С. 46-48.
6. Бобровская, Е. E., Бурова Н. H., Кон, В. Е. Предикторы осложненного течения и неблагоприятного прогноза у больных инфарктом миокарда / Е. Е. Бобровская, Н. Н. Бурова, В. Е. Кон // Артериальная гипертензия. - 2009. - Т. 15. - № 5. - С. 539-542.
7. Влияние инсулинорезистентности и нарушений углеводного обмена на течение острого периода инфаркта миокарда / Л. В. Квиткова, Т. С. Еленская, О. П. Благовещенская и др. // Проблемы эндокринологии. - 2011. - Т. 57. - № 2. -
С. 9-13.
8. Дедов, И. И., Балаболкин, М. И. Инсулиновая резистентность в патогенезе сахарного диабета типа 2 и медикаментозная возможность ее преодоления / И. И. Дедов, М. И. Балаболкин // Врач. - 2006. - № 11. - С. 3-9.
9. Демографический ежегодник России. 2012: стат. сб. // Росстат. -M.-
2012. -535 с.
10. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST: нац. рекомендации / Л.
3. Полонецкий, Л. Г. Гелис, В. П. Подпалов и др. // Кардиоваскулярная терапия и профилактика. - 2007. - Т. 6. - № 8. - Прил. 1 - 66 с.11. Динамика воспалительного процесса у больных с острым коронарным синдромом и стабильной стенокардией. Сообщение I. Биохимические, иммунологические и клинические аспекты / В. В. Кухарчук, К. А. Зыков, В. П. Масенко и др. // Кардиологический вестник. - 2007. - Т. 2. - С. 3-13.
12. Динамика провоспалительных и противовоспалительных цитокинов у больных с острым инфарктом миокарда / И. М.Фуштеин, С. Л. Подсевахина, О. В. Ткаченко и др. // Запорожская медицинская академия постдипломного образования. Медицина неотложных состояний. - 2010. - № 2. - С. 10-14.
13. Драпкина, О. M., Корнеева, О. H., Шептулина, А. Ф. Статины и сахарный диабет: риск и польза / О. М. Драпкина, О. Н. Корнеева, А. Ф. Шептулина // Кардиоваскулярная терапия и профилактика. - 2012. - № 6. - С. 85- 90.
14. Драпкина, О. M., Костюкевич, М. В. Статины и риск развития сахарного диабета / О. М. Драпкина, М. В. Костюкевич // Сахарный диабет. - 2012.-№2.-С. 77-82.
15. Драпкина, О. M., Смирин, В. И., Ивашкин, В. Т. Инсулинорезистентность и болезни сердца: есть ли связь? / О. М. Драпкина, В. И. Смирин, В. Т. Ивашкин // Фарматека. - 2009. - № 15. - С. 61-65.
16. Еленская, Т. С. Клиническое и прогностическое значение показателей инсулинорезистентности у больных инфарктом миокарда с подъёмом сегмента ST: автореф. дис. канд. мед. наук: 14.01.02, 14.01.05 / Т. С. Еленская // Новосибирск. -2012. -21 с.
17. Значимость факторов риска и сопутствующих заболеваний в течение острого инфаркта миокарда, ассоциированного с артериальной гипертонией / Л. Б.
Ким, Н. Г. Минина, Л. П. Цыба и др. 11 Российский кардиологический журнал. - 2007.-№2(64).-С. 47-51.
18. Инсулин и инсулинорезистентность: новые молекулы-маркеры и молекулы-мишени для диагностики и терапии заболеваний центральной нервной системы / А. Б. Салмина, Н. А. Лузина, Н. В. Кувачева и др. // Бюллетень сибирской медицины.
- 2013. - Т. - 12. - № 5. - С. 104-118.19. Инсулинорезистентность как ранний предиктор неблагоприятного течения хронической болезни почек недиабетической этиологии (обзор литературы) / Е. И. Леванковская, М. Ю. Швецов, А. В. Зилов и др. // Нефрология и диализ. -2010. -Т. 12. -№2. - С. 74-81.
20. Карпов, Р. С. Коронарная и сердечная недостаточность / под общей редакцией Р. С. Карпова. - Томск: STT, 2005. - 716 с.
21. Карпов, Ю. А. Инфаркт миокарда: на перекрестке мнений. Принципы ведения больных после инфаркта миокарда: профилактика осложнений с первых часов заболевания / Ю. А. Карпов // Consilium medicum. - 2006. - Т. 8. - № 5. - С. 62-65.
22. Климов, А. Н. Атеросклероз. Проблемы патогенеза и терапии / А. Н. Климов. - СПб.: Медицинская литература, 2006. - 246 с.
23. Кляритская, И. Л., Максимова, Е. В. Инсулинорезистентность и гепатит C / И. Л. Кляритская, Е. В. Максимова // Крымский терапевтический журнал. - 2009. - № 2 (13). - С. 32-37.
24. Кобалава, Ж. Д., Толкачева, В. В. Еипергликемия у пациентов с острым коронарным синдромом: современное состояние проблемы. Научные рекомендации Комитета по сахарному диабету Американской ассоциации сердца / Ж. Д. Кобалава, В. В. Толкачева // Кардиология. - 2009. - № 3. - С. 77-85.
25. Кремнева, Л. В., Шалаев, С. В. Еипергликемия у больных острым коронарным синдромом / Л. В. Кремнева, С. В. Шалаев // Атеротромбоз. - 2009. - Т. 2. -№1.-С. 86-94.
26. Майоров, А. Ю. Инсулинорезистентность в патогенезе сахарного диабета 2 типа / А. Ю. Майоров // Сахарный диабет. - 2011. - № 1. - С. 35-43.
27. Малиованова, И. М. Коронарный атеросклероз и статины / И. М. Малиованова // Креативная кардиология. - 2009. - № 2. - С. 118-130.
28. Митченко, Е. И., Романов, В. Ю. Исследование гиполипидемической эффективности, безопасности и влияния на инсулинорезистентность терапии аторвастатином у больных ИБС и сахарным диабетом типа 2 / Е. И. Митченко, В. Ю. Романов // Consilium medicum. - 2010. - Т. 4. - № 5. - С. 12-14.
29.
Мычка, В. Б., Чазова, И. Е. Влияние гиполипидемической терапии на инсулинорезистентность у пациентов с метаболическим синдромом / В. Б. Мычка, И. Е. Чазова// Системные гипертензии. -2004. -№ 1. - С. 16-18.30. Насонов, Е. Л. Иммунологические маркеры атеросклероза / Е. Л. Насонов // Терапевт, арх. - 2002. -№ 5. - С. 80-85.
31. Насонов, Е. Л. Иммунопатология застойной сердечной недостаточности: роль цитокинов / Е. Л. Насонов // Кардиология. - 1999. - №
3.-Р. 66-73.
32. Насонов, Е. Л. Маркеры воспаления и атеросклероз: значение C- реактивного белка / Е. Л. Насонов // Кардиология. - 1999. - № 2. - С. 81-85.
33. Насонов, Е. Л. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные) / Е. Л. Насонов, Е. В. Патокова, Е. Н. Александрова // Кардиология. - 2001 - № 6. - С. 60-64.
34. Оганов, Р. Г., Концевая, А. В., Калинина, А. М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации / Р. Г. Оганов, А.
В. Концевая, А. М. Калинина // Кардиоваскулярная терапия и профилактика. - 2011.-Т. 10.-№4.-С. 4-9.
35. Оганов, Р. Г., Масленникова, Г. Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения / Р. Г. Оганов, Г. Я. Масленникова / Кардиоваскулярная терапия и профилактика. - 2012. - Т. 11. -№ 1.-С. 5-10.
36. Оганов, Р. Г., Масленникова, Г. Я. Стратегия профилактики сердечнососудистых заболеваний в Российской Федерации / Р. Г. Оганов, Г. Я. Масленникова // Клиническая медицина. - 2012. - Т. 90. - № 3. - С. 4-7.
37. Острый коронарный синдром без подъемов сегмента ST на ЭКГ: разнонаправленные изменения показателей гемостаза при раннем применении аторвастатина и правастатина / Е. В. Покровская, Н. А. Грацианский, О. В. Аверков и др. // Кардиология. - 2003. - № 43. С. 4-13.
38. Ранние липидные и плеотропные эффекты аторвастатина у больных стабильной стенокардией с гиперхолестеринемией / С. В. Краснокутский, Г. И. Кочуев, И. В. Дяченко и др. // Вісник Сумського державного університету.
Сер. Медицина. - 2006. - Т. 86. - № 2. - С. 131-138.39. Роль инсулинорезистентности в развитии сердечно-сосудистых событий постинфарктного периода / Т. С. Еленская, О. П. Благовещенская, Л. В. Квиткова и др. // Кардиология в Белоруссии. - 2011. - № 5. - С. 104.
40. Сердечно-сосудистые заболевания в Российской Федерации на рубеже веков: смертность, распространенность, факторы риска / Л. А. Бокерия, И. Н. Ступаков, И. В. Самородская и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. - 2007. - Т. 8. - № 5. - С. 5-11.
41. Смоленская, О. Г., Макарова, В. Л., Зенин, Д. М. Развитие коронарного атеросклероза при нарушении углеводного обмена / О. Г. Смоленская, В. Л. Макарова, Д. М. Зенин // Кардиоваскулярная терапия и профилактика. - 2008. - Т. 7. - № 1. - С. 348.
42. Статины и сахарный диабет: цена сотрудничества / А. А. Александров, М. Н. Ядрихинская, С. С. Кухаренко и др. // Сахарный диабет. - 2012. - № 2. С. 70-76.
43. Тканевая инсулинорезистентность: степень выражения и взаимосвязь с факторами риска сердечно-сосудистых заболеваний: [Электронный ресурс] / М. Н. Мамедов, А. М. Олферьев, А. Н. Бриттов и др. // Российский кардиологический журнал. - 2000. - № 1. - URL: http://medi.ru/doc/6600110.htm (09.12.2012).
44. Фомин, В. В., Козловская, Л. В. С-реактивный белок и его значение в кардиологической практике / В. В. Фомин, Л. В. Козловская // Журнал доказательной медицины для практикующих врачей. - 2003. - №5. - P. 70-75.
45. Ханферян, Р. А. Модифицирующее влияние блокатора НЗ/Н4- гистаминовых рецепторов имопроксифана на уровень интерлейкиновой продукции в смешанных лимфоцитарных культурах у больных Q-позитивным инфарктом миокарда / Р. А. Ханферян // Журнал научных публикаций аспирантов и докторантов. - 2007. - №12. - С. 23-27.
46. Хельсинкская декларация Всемирной медицинской ассоциации [Электронный ресурс]: рек. для врачей по проведению биомед. исследований на людях. - URL: http:// doctors.of.lugansk.ua/Publ/Hels_D.html. Хельсинская декларация всемирной медицинской ассоциации (12.07.2013).
47. Шварц, В. Значение постпрандиальной гипергликемии в развитии сердечно-сосудистых заболеваний при сахарном диабете 2 типа / В. Шварц // Клин, медицина. - 2009. -№ 11. - С. 17-24.
48. Шестакова, М. В. Сахарный диабет и ишемическая болезнь сердца: влияние инсулинорезистентности и её коррекции на сердечно-сосудистый прогноз / М. В. Шестакова // Болезни сердца и сосудов. - 2006. - Т. 2. - № 2. -
С. 35-42.
49. Яковенко, Е. И. Влияние метаболических эффектов статинов на клинические проявления атеросклероза / Е. И. Яковенко, М. Н. Мамедов // Российский кардиолог, жури. - 2012. - Т. 2. - № 94. - С. 85-90.
50. Янчитайтите, JI., Растяните, Д. Прогноз у больных, перенесших инфаркт миокарда с зубцом Q нижней или передней локализации / Л. Янчитайтите, Д. Растяните // Кардиология. - 2007. - № 8. - С. 36-39.
51. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A / R. Kawaguchi, J. Yu, J. Honda et al. // Science. - 2007. - Vol. 315. - P. 820-825.
52. A novel serum protein similar to Clq produced exclusively in adipocytes / P. E. Sherer, S. Williams, M. Fogliano et al. // J Biol Chem. - 1995. - Vol. 270. - P. 26746-26749.
53. A rho-associated protein kinase, ROK-alpha, binds insulin receptor substrate-1 and modulates insulin signaling / S. Farah, Y. Agazie, N. Ohan et al. // J. Biol. Chem. - 1998. - Vol. 273. -P. 4740-4746.
54. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis / S. Verma, С. H. Wang, S. H. Li et al. // Circulation. - 2002. - Vol. 106 (8). -P. 913-919.
55. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine / J. L. Anderson, C. D. Adams, E. M. Antman et al. // Circulation. - 2007. - Vol. 116. - P. el48-e304.
56. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centres / С. B. Lawrence, A. C. Snape, F. M. Baudoin et al. // Endocrinology. -2002. - Vol. 143. -P. 155-162.
57. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates / К. E. Foster-Schubert, J. Overduin, С. E. Prudom et al. // Journal of Clinical Endocrinology and Metabolism. - 2008. - Vol. 93. - P. 1971-1979.
58. Adam, C. L., Findlay, P. A., Miller, D. W. Blood-brain leptin transport and appetite and reproductive. Neuroendocrine responses to intracerebroventricular leptin injection in sheep: influence of photoperiod / C. L. Adam, P. A. Findlay, D. W. Miller // Endocrinology. - 2006. - Vol. 147 (10). - P. 4589-4598.
59. Adipocyte-derived plasma protein, adiponectin acts as a platelet-derived growth factor-88-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell / Y. Arita, S. Kihara, N. Oucta et al. // Circulation. - 2002. - Vol. 105 (25). - P. 2893-2898.
60. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes / M. von Eynatten, J. G. Schneider, S. Hadziselimovic et al. // Diabetes Care. - 2005. - Vol. 28 (3). - P. 754-755.
61. Adipokines and insulin resistance / K. Rabe, M. Lehrke, K. G. Parhofer et al.//Mol. Med. -2008. - Vol. 14 (11-12).-P. 741-751.
62. Adipokines and risk of type 2 diabetes in older men / S. G. Wannamethee, G. D. Lowe, A. Rumley et al. // Diabetes Care. - 2007. - Vol. 30 (5). - P. 1200-1205.
63. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome / T. Kadowaki, T. Yamauchi, N. Kubota et al. // J. Clin. Invest. - 2006. - Vol. 116 (7). - P. 1784-1792.
64. Adiponectin and protection against type 2 diabetes mellitus / J. Spranger,
A. Kroke, M. Mohlig et al. // Lancet. - 2003. - Vol. 361 (9353). - P. 226-228.
65. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study / В. B. Duncan, M. I. Schmidt, J. S. Pankow et al. // Diabetes. - 2004. - Vol. 53 (9). - P. 2473-2478.
66. Adiponectin levels and risk of type 2 diabetes: a systematic reviewand meta-analysis / S. Li, H. J. Shin, E. L. Ding et al. // JAMA. - 2009. - Vol. 302. - P. 179-188.
67. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase / T. Yamauchi, J. Kamon, Y. Minokoshi et al. // Nat. Med. - 2002. - Vol. 8 (11). - P. 1288-1295.
68. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease / C. Zoccali, F. Mallamaci, G. Tripepi et al. // J. Am. Soc. Nephrol. - 2002. - Vol. 13. -P. 134-141.
69. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers / D. Rothenbacher, H. Hermann Brenner, W. Winfried Marz et al. // Eur. Heart J. - 2005. - Vol. 26. - P. 1640-1646.
70. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro / J. P. Bastard, M. Maachi, J. T. Van Nhieu et al. // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87 (5). - P. 2084-2089.
71. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production / M. W. Rajala, S. Obici, P. E. Scherer et al. // J. Clin. Invest. - 2003. - Vol. 111 (2). - P. 225-230.
72. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events / P.M. Ridker, N. Rifai, M. Clearfield et al. // N. Engl. J. Med. - 2001. - Vol. 344 (26). - P. 1959-1965.
73. Alessi, M. PAI-I and the metabolic syndrome: links, causes and consequences / M. Alessi, I. Juhan-Vague // Arterioscler. Thromb. Vase. Biol. - 2006. - Vol. 26 (10). -P. 2200-2207.
74. Ancestral effect on HOMA-IR levels quantitated in an American population of Mexican origin / H. Q. Qu, Q. Li, Y. Lu et al. // Diabetes Care. - 2012. - Vol. 35 (12).-P. 2591-2593.
75. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study / M. Hanefeld, N. Marx, A. Pfutzner et al. // J. Am. Coll. Cardiol. - 2007. - Vol. 49 (3). - P. 290-297.
76. Anti-tumor necrosis factor-a blockade improves insulin resistance in patients with rheumatoid arthritis / M. A. Gonzalez-Gay, J. M. De Matias, C. Gonzalez- Juanatey et al. // Clinical and Experimental Rheumatology. - 2006. - Vol. 24. - P. 83- 86.
77. Apo B/apo A-I ratio is better than LDL-C in detecting cardiovascular risk / G. P. Camevale Schianca, R. Pedrazzoli, S. Onolfo et al. // Nutr. Metab. Cardiovasc. Dis. -2011. - Vol. 21 (6). -P. 406-411.
78. Apo-B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel / P. J. Barter, C. M. Ballantyne, R. Carmena et al. // J. Intern. Med. - 2006. - Vol. 259 (3). - P. 247-258.
79. Amer, P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones / P. Amer // Trends in Endocrinology and Metabolism. - 2003. -Vol. 14 (3).-P. 137-145.
80. Association between high sensitivity C-reactive protein levels in serum and the 5-year-accumulative-risk of diabetes / H. H. Liu, D. Zhao, W. Wang et al. // Zhonghua Liu Xing Bing Xue Za Zhi. - 2011. - Vol. 32 (I). - P. 1-4.
81. Association between non-high density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatoiy Risk in Communities Study (CIRCS) / A. Kitamura, H. Noda, M. Nakamura et al. // J. Atheroscler. Thromb. - 2011. - Vol. 18 (6). - P. 454-463.
82. Association between semm C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction / T. Anzai, T. Yoshikawa, H. Kaneko et al. // Chest. - 2004. - Vol. 125 (2). - P. 384-389.
83. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men / A. Stancakova, T. Kuulasmaa, J. Paananen et al. // Diabetes. - 2009. - Vol. 58. - P. 2129-2136.
84. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies / J. Danesh, R. Collins, P. Appleby et al. // JAMA. - 1998. - Vol. 279. -P. 1477-1482.
85. Association of hemoglobin Alc with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk / K. T. Khaw,
N. Wareham, S. Bingham et al. // Ann. Intern. Med. - 2004. - Vol. 141. - P. 413-420.
86. Association of hypoadiponectinemia with coronary heart diseases in men / M. Kumada, S. Kihara, S. Sumitsuji et al. // Arterioscler. Thromb. Vase. Biol. - 2003. - Vol. 23(1).-P. 85-89.
87. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoom Study / M. B. Snijder, R. J. Heine, J. C. Seidell et al. // Diabetes Care. - 2006 - Vol. 29 (11). - P. 2498-2503.
88. Associations of adiponectin, resistin, and tumor necrosis factor-a with insulin resistance / M. F. Hivert, L. M. Sullivan, C. S. Fox et al. // Journal of Clinical Endocrinology and Metabolism. - 2008. - Vol. 93. - P. 3165-3172.
89. ASTEROID Investigators. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. / S. E. Nissen , S. J. Nicholls, I. Sipahi et al. // JAMA. - 2006. - Vol. 295 (13). - P. 1556-1565.
90. Athyros, V. G., Mikhailidis, D. P. Pharmacotherapy: statins and newonset diabetes mellitus—a matter for debate / V. G. Athyros, D. P. Mikhailidis // Nat. Rev. Endocrinol. -2012. - Vol. 8. -P. 133-134.
91. Atkinson L. L., Fischer M.A., Lopaschuk G.D. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl- CoA carboxylase-malonyl-CoA axis // J. Biol. Chem. - 2002. - Vol. 277. - P. 29424- 29430.
92. Atorvastatin but not pitavastatin significantly increases fasting plasma glucose in patients with type 2 diabetes and combined dyslipidemia (abstract) / V. Kryzhanovski, J. Gumprecht, B. Zhu et al. // J. Am. Coll. Cardiol. - 2011. - Vol. 57. - P. E575.
93. Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients / K. K. Koh, M. J. Quon, S. H. Han et al. // JACC. - 2010.-Vol. 55.-P. 134-139.
94. Atorvastatin decreases the coenzyme QlO level in the blood of patients at risk for cardiovascular disease and stroke / T. Rundek, A. Naini, R. Sacco et al. // Arch. Neurol. - 2004. - Vol. 61. - P. 889-892.
95. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes / C. H. Chu, J. K. Lee, H. C. Lam et al. // J Endocrinol Invest. - 2008. - Vol. 31. - P. 42-47.
96. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats / V. Wong, L. Stavar, L. Szeto et al. // Atherosclerosis. - 2006. - Vol. 184. - P. 348-355.
97. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A / R. Rodriguez-Calvo, E. Barroso, L. Serrano, T. Coll et al. // Hepatology. - 2009. - Vol. 49 (I). - P. 106-115.
98. Augmented expression of cardiotrophin-1 and its receptor component, gpl30, in both left and right ventricles after myocardial infarction in the rat / T. Aoyama, Y. Takimoto, D. Pennica et al. // J Mol Cell Cardiol. 2000. - Vol. 32. - P. 1821-1830.
99. Avogaro, A. Insulin resistance: trigger or concomitant factor in the metabolic syndrome / A. Avogaro // Panminerva Med. - 2006. - Vol. 48. - № I. - P. 3- 12.
100. Baud, V., Karin, M. Signal transduction by tumor necrosis factor and its relatives / V. Baud, M. Karin // Trends in Cell Biology. - 2001. - Vol. 11. - P. 372-377.
101. Beltowski, J. Leptin and atherosclerosis / J. Beltowski // Atherosclerosis. -
2006. - Vol. 189 (I). - P. 47-60.
102. Benefi cial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency / I. S. Farooqi, G. Matarese, G. M. Lord et al. // J. Clin. Invest. - 2002. - Vol. HO. - P. 1093- ПОЗ.
103. Berg, A. H., Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease / A. H. Berg, P. E. Scherer // Circulation Research. - 2005. - Vol. 96.-P. 939-949.
104. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women / B. J. Arsenault, J. S. Rana, E. S. Stroes et al. // J. Am. Coll. Cardiol. - 2009. - Vol. 55 (I). - P. 35-41.
105. Bourcier, T., Libby, P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells / T. Bourcier, P. Libby // Arterioscler Thromb. Vase. Biol. - 2000 - Vol. 20 (2). - P. 556-562.
106. Braunwald, E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials / E. Braunwald // Eur. Heart J. - 2012. - Vol. 33 (4). - P. 430-432.
107. Brown, J. E., Dunmore S. J. Leptin decreases apoptosis and alters BCL-2: Bax ratio in clonal rodentpancreatic beta-cells / J. E. Brown, S. J. Dunmore // Diabetes Metab. Res. Rev. - 2007 - Vol. 23 (6). - P. 497-502.
108. Calabro, P., Willerson, J. T., Yeh, E. T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells / P. Calabro, J. T. Willerson, E. T.Yeh et al. // Circulation. - 2003. -108. - P. - 1930-1932.
109. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions circulation / M. Gwechenberger, L. Mendoza., K. Youker, N. Frangogiannis, C. Smith, L. Michael, M. Entman // Circulation. - 1999. - Vol. 99.-P. 546-551.
HO. Cardiovascular Actions of Insulin / R. Muniyappa, M. Montagnani, К. K. Koh et al. // J. Quon. Endocr. Rev. - 2007. - Vol. 28 (3). - P. 463-491.
111. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial / P. M. Ridker, A. Pradhan, J. G. MacFadyen et al. // Lancet. - 2012. - Vol. 380. - P. 565-571.
112. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range / F. Ning, J. Tuomilehto, K. Pyorala et al. // Diabetes Care. - 2010. - Vol. 33. - P. 2211-2216.
113. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes / D. D. Waters, J. E. Ho, S. M. Boekholdt et al. // J. Am. Coll. Cardiol. - 2013. - Vol. 61. - P. 148-152.
114. Caro, F. Insulin resistance in obese and nonobese man / F. Caro // Clin. Endocrinol. Metab. - 1991. - Vol. 73 (4). -P. 691-695.
115. Case-control analysis of SNPs in GLUT4, RBP4 and STRA6: association of SNPs in STRA6 with type 2 diabetes in a South Indian population / A. K. Nair, D.
Sugunan, H. Kumar et al. // PLoS ONE. - 2010. - Vol. 5. - URL: http://el 1444doi: 10.1371/joumal.pone.OOl 1444.
116. Castelli, W. P. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study / W. P. Castelli // Can. J. Cardiol. - 1988. - Vol. 4. - suppl A. - P. 5A-10A.
117. Cefalu, W. T. Insulin resistance: cellular and clinical concepts / W. T Cefalu // Exp. Biol. Med. - 2001. - Vol. 226. - P. 13-26.
118. Chamberlain, L. H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes / L. H. Chamberlain // FEBS Lett. - 2001. - Vol. 507. - P. 357-361.
119. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice / P. J. Klover, T. A. Zimmers, L. G. Koniaris et al. // Diabetes. - 2003. - Vol. 52 (11). - P. 2794-2890.
120. Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3-L1 adipocytes / A. Xu, L. C. Wong, Y. Wang et al. // FEBS. - 2004. -Vol. 572.-P. 129-134.
121. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes / G. K. Shetty, P. A. Economides, E. S. Horton et al. // Diabetes Care. -
2004. - Vol. 27 (10). -P. 2450-2457.
122. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts / В. H. Chen, Y. Song, E. L. Ding et al. // Diabetes Care. - 2009. - Vol. 32 (2). - P. 329-336.
123. Circulating non-esterified fatty acid level as a predictive risk factor for sudden death in the population / X. Jouven, M. A. Charles, M. Desnos et al. // Circulation. -2001. - Vol. 104 (7). -P. 756-761.
124. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly / E. Ingelsson, J. Sundstrom, H. Melhus et al. // Atherosclerosis. - 2009. - Vol. 206. - P. 239-244.
125. Colbert, J. D., Stone, J. A. Statin use and the risk of incident diabetes mellitus: a review of the literature / J. D. Colbert, J. A. // Stone Can. J. Cardiol. - 2012. - Vol. 28.-P. 581-589.
126. Collet, J. P., Montalescot G., Vicaut E. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality / J. P. Collet, G. Montalescot, E. Vicaut // Circulation. - 2003. - Vol. 108. - P. 391-394.
127. Common variations in the genes encoding C-reactive protein, tumor necrosis factor-а, and interleukin-6, and the risk of clinical diabetes in the Women's Health Initiative Observational Study / K. K. Chan, K. Brennan, N. Y. You et al. // Clin. Chem. -2011. - Vol. 57 (2). -P. 317-325.
128. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) / P. H. Jones, M. H. Davidson, E. A. Stein et al. // Am. J. Cardiol. - 2003. - Vol. 92 (2). - P. 152-160.
129. Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. - 2006. - Vol. 106 (I)-P. 16-20.
130. Correlates of acute insulin resistance in the early phase of non-diabetic ST- elevation myocardial infarction / C. Lazzeri, S. Valente, M. Chiostri et al. // Diabetes and Vascular Disease Research. - 2011. - Vol. 8 (I). - P. 35-42.
131. Correlation analysis of increase in serum level of leptin with that of C reactive protein, troponin T and endothelin in patients with acute myocardial infarction / G. T. Yan, H. Xue, J. Lin et al. // Circulation Research. - 2005. - Vol. 17(9). - P. 2-530.
132. Cowley, M. A. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis / M. A. Cowle // Neuron. - 2003. - Vol. 37. - P. 649-661.
133. C-reactive protein accelerates the progression of atherosclerosis in apohpoprotein E-deficient mice / A. Paul, K. W. Ко, L. Li et al. // Circulation. - 2004. - Vol. 109.-P. 647-655.
134. C-reactive protein and incident cardiovascular events among men with diabetes / M. B. Schulze, E. B. Rimm, T. Li et al. // Diabetes Care. - 2004 - Vol. 27 (4). -P. 889-894.
135. C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients / A. Taniguchi, S. Nagasaka, M. Fukushima et al. // Metabolism. - 2002.-Vol. 51 (12).-P. 1578-1581.
136. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction / T. Anzai, T. Voshikawa, H. Shiraki at al. // Circulation. - 1997. - Vol. 96. - P. 778-784.
137. C-reactive protein attenuates endothelial progenitor cell survival,
differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease / S. Verma, M. A. Kuliszewski, S. H. Li et al. // Circulation. -2004. - Vol. 109 (17). -P. 2058-2067.
138. C-reactive protein augments hypoxia-induced apoptosis through
mitochondrion-dependent pathway in cardiac myocytes / J. Yang, J. Wang, S. Zhu et al. // Mol. Cell. Biochem. - 2008. - Vol. 310 (5). - P. 215-226.
139. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? J. S. Yudkin, C. D. Stehouwer, J. J. Emeis et al. // Arterioscler. Thromb. Vase. Biol. - 1999. - Vol. 19. - P. 972-978. (СРБ предсказывает диабет)
140. C-reactive protein in the arterial intima: role of C-reactive protein receptor- dependent monocyte recruitment in atherogenesis / M. Torzewski, C. Rist, R. F. Mortensen et al. // Arterioscler. Thromb. Vase. Biol. - 2000. - Vol. 20. - P. 2094-2099.
141. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes thereby impairing the insulin signalling pathway that promotes glucose transport / C. D’Alessandris, R. Lauro, I. Presta et al. // Diabetologia. - 2007. - Vol. 50. - P. 840-849.
142. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg
Cohort Study, 1984 to 1992 / W. Koenig, M. Sund, M. Frohlich et al. // Circulation. -
1999. -Vol. 99.-P. 237-242.
143. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study / J. Jeppesen, T. W. Hansen, M. H. Olsen et al. // European Journal of Cardiovascular Prev. Rehabilitation. - 2008. - Vol. 15 (5). - P. 594-598.
144. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus / A. D. Pradhan, J. E. Manson, N. Rifai et al. // JAMA. - 2001. - Vol. 286. - P. 327-334. (CPБ предсказывает диабет)
145. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women / P. M. Ridker, J. E. Birring, N. R. Cook et al. // Circulation. - 2003. - Vol. 107. - P. 391-397.
146. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion / T. Barret, J. Herman, R. Marks et al. // The J. of Pharmacology and experimental therapeutics. - 2002. - Vol. 303 (3). - P.1007-1013.
147. Critical steps in cellular fatty acid uptake and utilization / G. J.Van der Vusse, M. van Bilsen, J. F. Glatz et al. // Mol. Cell. Biochem. - 2002. - Vol. 239. - P. 9-15.
148. DeFronzo, R. A., Tobin, J. D., Andres, R. The glucose clamp technique: a method for quantifying insulin secretion and resistance / R. A. DeFronzo, J. D. Tobin,
R. Andres // Am. J. Physiol. - 1979. - Vol. 6. - P. E214-E223.
149. Devaraj, S. Chan, E., Jialal, I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome / S. Devaraj, E. Chan, I. Jialal // The Journal of Clinical Endocrinology Metabolism. - 2006. - Vol. 91 (I I). - P. 4489-4496.
150. Devaraj, S., Xu, D. Y., Jialal, I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis / S. Devaraj, D. Y. Xu, I. Jialal // Circulation. - 2003. - Vol. 107. - P. 398-404.
151. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins / D. T. Ко, H. C. Wijeysundera, C. A. Jackevicius et al. // Circ. Cardiovasc. QuaL Outcomes. -
2013. - Vol. 6 (3). -P. 315-322.
152. Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program / K. J. Mather, T. Funahashi, Y. Matsuzawa et al // Diabetes. - 2008. - Vol. 57 (4). - P. 980-986.
153. Diagnosing insulin resistance in the general population / K. McAuley, S. Williams, J. Mann et al. // Diabetes Care. - 2001. - Vol. 24. - P. 460-464.
154. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression / E. J. Park, J. H. Lee, G. Y. Yu et al. // Cell. - 2010.-Vol. 140.-P. 197-208.
155. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes / N. V. Chu, A. P. Kong, D. D. Kim et al. // Diabetes Care. - 2002. - Vol. 25. - P. 542-549. (Сахароснижающие препараты эффективно снижают CPБ)
156. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients / K. K. Koh, M. J. Quon, S. H. Han et al. // Atherosclerosis. - 2009. - Vol. 204 (2). - P. 483-490.
157. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance / G. S. Hotamisligil, P. Arner, R. L. Atkinson et al. // Diabetes. - 1997. - Vol. 46. - P. 451-455. ФИО альфа и ИР
158. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis / W. L. Baker, R. Talati, С. M. White et al. // Diabetes Res. Clin. Pract. - 2010. - Vol. 87. - P. 98-107.
159. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake / W. Mauser, N. Perwitz, B. Meier et al. // Eur. J. Pharmacol. - 2007. - Vol. 564.
P. 37-46.
160. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions / D. Kawanami, K. Maemura, N. Takeda et al. // Biochem. Biophys. Res. Commun. - 2004. - Vol. 314 (2). -P.415-419.
161. Disruption of the plasminogen activator inhibitor I gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetes ob/ob mice / K. Schafer, K. Fujisawa, S. Konstantindes et al. // FASEB J. - 2001. - Vol. 15. - P. 1840-1842.
162. Distinct effects of pravastatin, atorvastatin and simvastatin on insulin secretion from a beta-cell line, MIN6 cells / M. Ishikawa, F. Okajima, N. Inoue et al. // J. Atheroscler. Thromb. - 2006. - Vol. 13 (6). - P. 329-335.
163. Disulfide-dependent multimeric assembly of resistin family hormones / S.
D. Patel, M. W. Rajala, L. Rossetti et al. // Science. - 2004. - Vol. 304 (5674). - P. 1154-1158.
164. Dluhy, R. G., McMahon, G. T. Intensive glycemic control in the ACCORD and ADVANCE trials / R. G. Dluhy, G. T. McMahon // N. Engl. J. Med. - 2008. - Vol. 358 (24). - P. 2630-2633. не выявлено преимуществ агрессивного гликемичекого контроля
165. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project / N. Rautio, J. Jokelainen, H. Oksa et al. // BMJ Open. - 2012. - Vol. 2. - P. e001472.
166. Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity / К. H. Kim, L. Zhao, Y. Moon et al. // Proc. Natl. Acad. Sci. U S A. - 2004. - Vol. 101 (17). -P. 6780-6785.
167. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation / C. Tsigos, D. A. Papanicolaou, I. Kyrou et al. // J. Clin. Endocrinol. Metab. - 1997. - Vol. 82 (12). -P. 4167-4170.
168. Dandona, P. Effects of Antidiabetic and Antihyperlipidemic Agents on C- Reactive Protein / P. Dandona // Mayo Clin Proc. - 2008. - Vol. 83 (3). - P. 333-342.
169. Effect of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with MDDM / F. Ofei, S. Hurel, J. Newkirk et al. // Diabetes. - 1996. - Vol. 45. - P. 881-885.
170. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity / D. C. Chan, G. F. Watts, P. H. R. Barrett et al. //Clinical Chemistry. - 2002. - Vol. 48 (6). - P. 877-883.
171. Effect of atorvastatin on hs-CRP in acute coronary syndrome / Gupta A., Dinesh K. Badyal, Prem P. Khosla et al. // British J. Clin. Pharmacol. - 2008. - Vol. 66 (3).-P.411-413.
172. Effect of atorvastatin withdrawal on circulating coenzyme QlO concentration in patients with hypercholesterolemia / C. S. Chu, H. S. Kou, C. J. Lee et al. // Biofactors. - 2006. - Vol. 28. - P. 177-184.
173. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease / G. Marazzi, M. Wajngarten, C. Vitale et al. // Int. J. Cardiol. - 2007. - Vol. 120 (I). - P. 79-84.
174. Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome / F. Fallo, A. Scarda, N. Sonino et al. // Eur. J. Endocrinol. - 2004. -Vol. 150.-P. 339-344.
175. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI- PRO VE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy / С. M. Gibson, Y. B. Pride, C. P. Hochberg et al. // J. Am. Coll. Cardiol. - 2009. - Vol. 54 (24). - P. 2290-2295.
176. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study / J. Shepherd, P. Barter, R. Carmena et al. // Diabetes Care. - 2006. - Vol. 29. - P. 1220-1226.
177. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study) / S. Yusuf, S. Hawken, S. Ounpuu et al. // Lancet. - 2004. - Vol. 364 (9438). - P. 937-952.
178. Effect of pravastatin on the development of diabetes and adiponectin production / T. Takagi, M. Matsuda, M. Abe et al. // Atherosclerosis. - 2008. - Vol. 196. -P. 114-121.
179. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus / S. M. Haffner, A. S. Greenberg, W. M. Weston et al. // Circulation. - 2002. - Vol. 106. - P. 679-684.
180. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin Alc levels in patients with non-ischaemic chronic heart failure / T. Tsutamoto, M. Yamaji, C. Kawahara et al. // Eur. J. Heart. Fail. - 2009. - Vol. 11 (12). - P. 1195-1201.
181. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients / R. Sukhija, S. Prayaga, M. Marashdeh et al. // J. Investig. Med. - 2009. - Vol. 57. -P. 495-499.
182. Effects of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM / F. Ofei, S. Hurel, J. Newkirk et al. // Diabetes. - 1996. - Vol. 45. - P. 881-885.
183. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes / A. Takaguri, K. Satoh, M. Itagaki et al. // J. Pharmacol. Sci. - 2008. - Vol. 107. - P. 80-89.
184. Effects of atorvastatin on apelin, visfatin (nampt), ghrehn and early carotid atherosclerosis in patients with type 2 diabetes / N. P. Kadoglou, N. Sailer, A. Kapelouzou et al. // Acta Diabetol. - 2012. - Vol. 49 (4). - P. 269-276.
185. Effects of free fatty acids on glucose transport and IRS-l-associated phosphatidyl inositol 3-kinase activity / A. Dresner, D. Laurent, M. Marcucci et al. // J. Clin. Invest. - 1999. - Vol. 103 (2). -P. 253-259.
186. Effects of intensive glucose lowering in type 2 diabetes. / H. C. Gerstein, M. E. Miller, R. P. Byington et al. // N. Engl. J. Med. - 2008. - Vol. 358 (24). - P. 2545-2559.
187. Effects of physiologic leptin administration on markers of inflammation, platelet activation and platelet aggregation during caloric deprivation / B. Canavan, R.
O. Salem, S. Schurgin et al. // J. Clin. Endocrinol. Metab. - 2005. - Vol. 90 (10). - P. 5779-5785.
188. Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes / H. Hirose, T. Kawai, Y. Yamamoto et al. // Metabolism. - 2002. - Vol. 51. - P. 314-317.
189. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial /1. Raz, P. W. Wilson, K. Strojek et al. // Diabetes Care. - 2009. - Vol. 32. - P. 381-386.
190. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control / M. Nakata, S. Nagasaka, I. Kusaka et al. // Diabetologia. - 2006. - Vol. 49 (8). - P. 1881-1892.
191. Effects of TNF-a neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome / J. Lo, L. E. Bernstein, B. Canavan et al. // American Journal of Physiology, Endocrinology and Metabolism. - 2007. - Vol. 293. -
P. E102-E109.
192. Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectin / K. Miyagishima, S Hiramitsu, S. Kato et al. // J. Int. Med. Res. - 2007. - Vol. 35 (4). - P. 534-539.
193. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis / P. M. Kearney, L. Blackwell, R. Collins et al. // Lancet. - 2008. - Vol. 371. -P. 117-125.
194. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure / P. A. Kavsak, A. R. MacRae, A. M. Newman et al. // Clin. Biochem. - 2007. - Vol. 40 (5-6). - P. 326-329.
195. Elevated C-reactive protein levels in overweight and obese adults / M. Visser, L. M. Bouter, G. M. McQuillan et al. // JAMA. - 1999. - Vol. 282. - P. 2131- 2135.
196. Elevated levels of acute-phase proteins and plasminogen activator inhibitor I predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study / A. Festa, R. Jr. D’Agostino, R. P. Tracy et al. // Diabetes. - 2002. - Vol. 51 (4). -R 1131-1137.
197. Elevated plasma free fatty acids predict sudden cardiac death: a 6,85-year follow-up of 3315 patients after coronary angiography / S. Pilz, H. Schamagl, B. Tiran et al. // Eur. Heart. J. - 2007. - Vol. 28 (22). - P. 2763-2769.
198. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over I-year follow-up / R. Krecki, M. Krzeminska-Pakula, J. Z. Peruga et al. // Med. Sci. Monit. -2011. - Vol. 17 (I). -P. CR26-CR32.
199. Elevated retinol binding protein-4 levels are associated with metabolic syndrome in Chinese people / Q. Qi, Z. Yu, X. Ye et al. // J. Clin. Endocrin. Metab. -
2007. - Vol. 92. - P. 4827-4834.
200. Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction / M. Sasaki, T. Otani, M. Kawakami et al. // Metabolism. - 2010. - Vol. 59. -P. 527-532.
201. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone / E. Arvat, M. Maccario, L. Di Vitro et al. // J. Clin. Endocrin. Met. - 2001. - Vol. 86. - P. 1169-1174.
202. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial mice infarction / K. M. Kurrelmeyer, L. H. Michael, G. Baumgarten et al. // Proc. Natl. Acad. Sci. USA. -2000. - Vol. 10. -P. 5456-546E
203. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes / A. Fujinami, H. Obayashi, K. Ohta et al. // Clin. Chim. Acta. - 2004. - Vol. 339 (I). - P. 57-63.
204. Ethnic differences in C-reactive protein concentrations / K. A. Hedgepeth,
D. M. Lloyd-Jones, A. Colvin et al. // Clin Chem. - 2008. - Vol. 54. - P. 1027-1037.
205. Evidence for a role of tumor necrosis factor a in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease / S. Jovinge,
A. Hamsten, P. Tomvall et al. // Metabolism. - 1998. - Vol. 47. - P. 113-118.
206. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial mpture and left ventricular dysfunction / M. Sun, F. Dawood, W. H. Wen et al. // Circulation. - 2004. - Vol. 110. - P. 3221-3228.
207. Exogenous ghrelin modulates release of pro-inflammatory cytokones in LPS-stimulated macrophages through distinct signalling pathways / T. Waseem, M. Duxbury, H. Ito et al. // Surgery. - 2008. - Vol. 143. - P. 334-342.
208. Extraadipocyte leptin release in human obesity and its relation to sympathoadrenal function / N. Eikelis, G. Lambert, G. Wiesner et al. // Am. J. Physiol. Endocrinol. Metab. - 2004. - Vol. 286 (5). - P. 744-752.
209. Fantuzzi, G. Adipose tissue, adipokines, and inflammation/ G. Fantuzzi // J. Allergy and Clinical Immunology. - 2006. - Vol. 115 (5). - P. 911-919.
210. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study / J. B. Meigs, D. M. Nathan, R. B. Sr. D’Agostino et al. // Diabetes Care. - 2002. - Vol. 25. - P.1845-1850. Сравнение трех показателей
211. Fasting plasma leptin, tumor necrosis factor- receptor 2, and monocyte chemoattracting protein I concentration in a population of glucose-tolerant and glucose- intolerant women: impact on cardiovascular mortality / L. Piemonti, G. Calori, A. Mercalli et al. // Diabetes Care. - 2003. - Vol. 26 (10). - P. 2883-2889.
212. Feingold, K. R., Gmnfeld, C. Tumor necrosis factor-a stimulates hepatic Hpogenesis in the rat in vivo / K. R. Feingold, C. Gmnfeld // Journal of Clinical Investigation. - 1987. - Vol. 80. -P. 184-190.
213. Fernandes, J., Rilcart, W. Insulin resistance and chronic cardiovascular inflammatory syndrome / J. Fernandes, W. Rilcart // Endocr. Rev. - 2003. - Vol. 24. - P. 278-301.
214. Fernandez-Real, J. M., Moreno, J. M., Ricart, W. Circulating retinolbinding protein-4 concentration might reflect insulin resistance-associated iron overload / J. M. Fernandez-Real, J. M. Moreno, W. Ricart // Diabetes. - 2008. - Vol. 57. - P. 1918-1925.
215. Flachs, P. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet / P. Flachs // Diabetologia. - 2006. - Vol. 49. - P. 394-397.
216. Food fails to suppress ghrelin levels in obese humans / P. J. English, M. A. Ghatei, I. A. Malik et al. // J Clin Endocrin Met. - 2002. - Vol. 87. - P. 2984-2987.
217. Frangogiannis, N. The immune system and cardiac repair / N. Frangogiannis // Pharmacological Research. - 2008. - Vol. 58 (2). - P. 88-111.
218. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy / R. T. de Jongh, E. H. Seme, R. G. Ijzerman et al. // Diabetes. - 2004. - Vol. 53 (I I). - P. 2873- 2882.
219. Fujimaki, S., Kanda, T., Fujita, K. The significance of measuring plasma leptin in acute myocardial infarction / S. Fujimaki, T. Kanda, K. Fujita // J. Int. Med.
Res. -2001. - Vol. 29 (2). -P. 13-108.
220. Gabay, C., Kushner, I. Acute phase proteins and other systemic responses to inflammation / C. Gabay, I. Kushner // N. Engl. J. Med. - 2009. - Vol. 340. - P. 1376-1381.
22 E Generation of C-reactive protein and complement components in atherosclerotic plaques / K. Yasojima, C. Schwab, E. G. McGeer et al. // Am. J. Pathol. -2001. - Vol. 158. -P. 1039-1051.
222. Genetic deletion of IL-6 ameliorates left ventricular dysfunction and remodeling after a reperfused myocardial infarction / H. Taher, Y. Guo, S. K. Sanganalmath et al. // Circulation. - 2008. - Vol. 118. - P. 290.
223. Ghrelin action in brain controls adipocyne metabolism / C. Theander- Carrillo, P. Wiedmer, P. Cettour-Rose et al. // J Clin Invest. - 2006. - Vol. 116. - P. 1983-1993.
224. Ghrelin and leptin: a link between obesity and allergy / K. Matsuda, Y. Nishi, Y. Okamatsu et al. // Journal of allergy and clinical Immunology (St Louis MO). - 2006. - Vol. 117 (3). - P. 705-706.
225. Ghrelin is a growth-hormone-releasing acylated peptide from stomach / M. Kojima, H. Hosoda, Y. Date et al. // Nature. - 1999. - Vol. 402. - P. 656-660.
226. Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential / T. Yada, K. Dezaki, H. Sone et al. // Curr. Diabetes. Rev. - 2008. -Vol. 4. -P. 18-23.
227. Ghrelin response to carbohydrate-enriched breakfast is related to insulin / W. A. Blom, A. Stafleu, C. de Graaf et al. // Am. J. Clin. Nutr. - 2005. - Vol. 81. - P. 367-375.
228. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine and dietary manipulations / H. M. Lee, G. Wang, E. W. Englander et al. // Endocrinology. - 2002. - Vol. 143. -P. 185-190.
229. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans / Y. Date, M. Kojima, H. Hosoda et al. // Endocrinology. - 2000. - Vol. 141. - P. 4255- 4261.
230. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia / R. B. Goldberg, D. M. Kendall, M. A. Deeg et al. // Diabetes Care. - 2005. - Vol. 28. - P. 1547-1554.
231. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe // Lancet. - 1999. - Vol. 354. - P. 617-621.
232. Glucosedependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin / L. O’Rourke, L. M. Gronning, S. J. Yeaman et al. // J. Biol. Chem. - 2002. - Vol. 277 (45). - P. 42557-42562.
233. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults / E. Selvin, M. W. Steffes, H. Zhu et al. // N. Engl. J. Med. - 2010. - Vol. 362. - P. 800-811.
234. Goldfine, A. B. Statins: is it really time to reassess benefits and risks? / A.
B. Goldfme // N. Engl. J. Med. - 2012. - Vol. 366. - P. 1752-1755.
235. Gordon, J. R., Galli, S. J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/ cachectin / J. R. Gordon, S. J. Galli // Nature. - 1990. - Vol. 346. -P. 274-276.
236. Gosman, G. G., Katcher, H. I., Legro, R. S. Obesity and the role of gut and adipose hormones in female reproduction / G. G. Gosman, H. I. Katcher, R. S. Legro // Hum. Reprod. Update. - 2006. - Vol. 12 (5). - P. 585-601.
237. Gould, J. M., Weiser, J. N. Expression of C-reactive protein in the human respiratory tract / J. M. Gould, J. N. Weiser // Infect Immun. - 2001. - Vol. 69. - P.
1747-1754.
238. Haemoglobin Alc levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts / R. Santos-Oliveira, C. Purdy, M. P. da Silva et al. // Diabetologia. - 2011. - Vol. 54. - P. 1327-1334.
239. Hajer, G. R., van Haeften, T. W., Visseren, F. L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases / G. R. Hajer, T. W. van Haeften,
F. L. Visseren // Eur. Heart. J. - 2008. - Vol. 29 (24). - P. 2959-2971.
240. Hansson, G. K. Inflammation, Atherosclerosis, and Coronary Artery Disease / G. K. Hansson // N. Engl. J. Med. - 2005. - Vol. 352. - P. 1685-1690.
241. Hemostasis and fibrinolysis in non-diabetic overweight and obese menand women. Is there still a role for leptin? /1. Mertens, R. V. Considine, M. van der Planken et al. // Eur. J. Endocrinol. - 2006. - Vol. 155 (3). - P. 477-484.
242. High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study / G. Walldius, I. Jungner, I. Holme et al. // Lancet. - 2001. - Vol. 358 (9298). - P. 2026- 2033.
243. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator / V. R. Sopasakis, M. Sandqvist, B. Gustafson et al. // Obes Res. - 2004. - Vol. 12. - P. 454-460.
244. High serum leptin is associated with attenuated coronary vasoreactivity / J. Sundell, R. Huupponen, 0. T. Raitakari et al. // Obes. Res. - 2003. - Vol. 11. - P. 776- 782.
245. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy / M. S. Sabatine, S. D. Wiviott, D. A. Morrow et al. // Circulation. - 2004. - Vol. HO. -P. S834.
246. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial / T. R. Pedersen, 0. Faergeman, J. P. Kastelein et al. // JAMA. - 2005. - Vol. 294 (19). - P. 2437-2445.
247. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study / M .Soinio, J. Mamiemi, M. Laakso et al. // Diabetes Care. - 2006. - Vol. 29 (2). - P. 329-333.
248. Holman, G. D., Kasuga, M. From receptor to transporter: insulin signalling to glucose transport / G. D. Holman, M. Kasuga // Diabetologia. - 1997. - Vol. 40. - P. 1991-1003.
249. HOMA-IR and QUICKI: decide on a general standard instead of making further comparisons / S. M. Rossner, M. Neovius, A. Mattsson et al. // Acta Paediatr. - 2010. - Vol. 99 (I I). - P. 1735-1740.
250. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study / A. J. Hanley, K. Williams, M. P. Stem et al. // Diabetes Care. - 2002. - Vol. 25 (7). - P. 1177-1184.
251. Hotamisligil, G. S., Shargill, N. S., Spiegelman, В. M. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance / G. S. Hotamisligil, N. S. Shargill, В. M. Spiegelman // Science. -1993. - Vol. 259. - P. 87- 91.
252. Hsueh, W. A. Law, R. E. Cardiovascular risk continuum: implications of insulin resistance and diabetes / W. A. Hsueh, R. E. Law // Am. J. Med. - 1998. - Vol. 105 (I).-P. 4-14.
253. Hulten, E., Jackson, J. L., Douglas, K. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome / E. Hulten, J. L. Jackson, K. Douglas // Arch IntemMed. -2006. Vol. 166. -R 1814-1821.
254. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells / A. Abderrahmani, G. Niederhauser, D. Favre et al. // Diabetologia. - 2007. - Vol. 50 (6).-P. 1304-1314.
255. Human leptin enhances activation and proliferation of human circulating T lymphocytes / C. Martin-Romero, J. Santos-Alvarez, R. Gobema et al. // Cell Immunol. -2000.-Vol. 199.-P. 15-24.
256. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease / K. Yasojima, C. Schwab, E. G. McGeer et al. // Brain Res. -
2000. - Vol. 887. -P. 80-89.
257. Human RBP4 adipose tissue expression is gender specific and influenced by leptin / K. Kos, S. Wong, B. Tan et al. // Clinical Endocrinology. - 2010. - Vol. 74. -P. 197-205.
258. Huxley, R., Barzi, F., Woodward, M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 38 prospective cohort studies / R. Huxley, F. Barzi, M. Woodward // B.M.J. - 2006. - Vol. 332. - P. 73-78.
259. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin: potential role in the modulation of its insulin- sensitizing activity / Y. Wang, A. Xu, C. Knight et al. // J. Biol. Chem. - 2002. - Vol. 211.-V. 19521-19529.
260. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population. The Paris Prospective Study, 15-year follow up / A. Fontbonne, M. A. Charles, N. Thibault et al. // Diabetologia. - 1991. - Vol. 34. - P. 356-361.
261. Hyperinsulinemia in patients with coronary heart disease in absence of overt risk factors / C. R. Ariza, A. C. Frati, G. Gomez et al. // Arch. Med. Res. - 1997. - Vol. 28 (I).-P. 115-119.
262. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia / C. Weyer, T. Funahashi, S. Tanaka et al. // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86. - P. 1930-1935.
263. IKK-b links inflammation to obesity-induced insulin resistance / M. C. Arkan, A. L. Hevener, F. R. Greten et al. // Nature Medicine. - 2005. - Vol. 11. - P. 191-198.
264. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and со-regulated acute-phase proteins but not TNF-a or its receptors / S. Muller, S. Martin, W. Koenig et al. // Diabetologia. - 2002. - Vol. 45. -P. 805-812.
265. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis / V. G. Athyros, A. I. Hatzitolios, A. Karagiannis et al. // Arch. Med. Sci. - 2011. - Vol. 7. - P. 984-992.
266. In vivo transfer of soluble TNF-alpha receptor I gene improves cardiac function and reduces infarct size after myocardial infarction in rats / M. Sugano, K. Tsuchida, T. Hata et al. // Faseb. J. - 2004. - Vol. 18. - P. 911-913.
267. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham / W. P. Castelli, R. J. Garrison, P. W. Wilson et al. // JAMA. - 1986. - Vol. 256 (20).-P. 2835-2838.
268. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors / D. Mozaffarian, R. M. Marfisi, G. Levantesi et al. // Lancet. - 2007. - Vol. 370. - P. 667- 675.
269. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals / G. Perseghin,
A. Caumo, М. Caloni et al. // Journal of Clinical Endocrinology and Metabolism. -
2001. - Vol. 86. -P. 4776-4781.
270. Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction / T. Takahashi, T. Anzai, H. Kaneko et al. // Am J. Physiol. Heart. Circ. Physiol. - 2010. - Vol. 299 (6). - P. H1795-H1804.
271. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor / K. K. Wu, T. J. Wu, J. Chin et al. // Atherosclerosis. - 2005. -Vol. 181-P. 251-259.
272. Increased number of islet-associated macrophages in type 2 diabetes / J. A. Ehses, A. Perren, E. Eppler et al. // Diabetes. - 2007 - Vol. 56 (9). - P. 2356-2370.
273. Increased plasma-soluble tumor necrosis factor-а receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects / M. Straczkowski, I. Kowalska, A. Stepien et al. // Diabetes Care. - 2002- Vol. 25. - P. 1824-1828.
274. Increased serum leptin concentrations in patients with chronic stable angina pectoris and ST-elevated myocardial infarction / F. Taneli, S. Yegane, C. Ulman et al. // Angiology. - 2006. - Vol. 57 (3). - P. 267-272.
275. Increased thrombosis after arterial injury in human C-reactive protein- transgenic mice / H. D. Danenberg, A. J. Szalai, R. V. Swaminathan et al. // Circulation. -2003. - Vol. 108. -P. 512-515.
276. Increases in serum unbound free fatty acid levels following coronary angioplasty / A. M. Kleinfeld, D. Prothro, D. L. Brown et al. // Am. J. Cardiol. - 1996. -Vol. 78(12). -P. 1350-1354.
277. Independent association between plasma leptin and C-reactive protein in healthy humans / A. S. Shamsuzzaman, M. Winnicki, R. Wolk et al. // Circulation. - 2004. - Vol. 109. - P. 2181-2185.
278. Induction of adipocyte complement related protein of 30 kilodaltons by PPAR gamma agonists: a potential mechanism of insulin sensitization / T. P. Combs, J. A. Wagner, J. Berger et al. // Endocrinology. - 2002. - Vol. 143. - P. 998-1007.
279. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury / G. L. Kukielka, C. W. Smith, A. M. Manning et al. // Circulation. - 1995. - Vol. 92. - P. 1866-1875.
280. Infection and inflammation-induced proatherogenic changes of lipoproteins / W. Khovidhunkit, R. A. Memon, K. R. Feingold et al. // J. Infect. Dis. - 2000. - Vol. 181 (3). — P. S462-S472.
281. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study / G. Engstom, L. Stavenow, B. Hedblad et al. // Diabetes. - 2003. - Vol. 52 (2). - P. 442-447.
282. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment / B. J. Ansell, M. Navab, S. Hama et al. // Circulation. - 2003. - Vol. 108 (22). - P. 2751-2756.
283. Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion / C. Bickel, H. J. Rupprecht, S. Blankenberg et al. // Int J. Cardiol. - 2002. - Vol. 82 (I). - P. 25-31.
284. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus / T. Yamakawa, T. Takano, S. Tanaka et al. // J. Atheroscler. Thromb. -2008.-Vol. 15.-269-275.
285. Influence of TNF-a and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans / R. Krogh-Madsen, P. Plomgaard, K. Moller et al. // Am. J. Physiol. Endocrinol. Metab. -2006. - Vol. 291 (I). -P. E108-E114.
286. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature / Z. Liu, J. Liu, L. A. Jahn et al. // J. Clin. Endocrinol. Metab. - 2009. - Vol. 94 (9). - P. 3543-3549.
287. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells / T. Yada, M. Nakata, T. Shiraishi et al. // Br. J. Pharmacol. - 1999. - Vol. 126 (5).-P. 1205-1213.
288. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltagegated calcium channel function in pancreatic beta-cells / F. Xia, L. Xie, A. Mihic et al. // Endocrinology. -2008. - Vol. 149. -P. 5136-5145.
289. Inhibition of glucose- and calcium-induced insulin secretion from betaTC3 cells by novel inhibitors of protein isoprenylation / R. Amin, H. Q. Chen, M. Tannous et al. // J. Pharmacol. Exp. Ther. - 2002. - Vol. 303. - P. 82-88.
290. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor / N. Teraoka, M. Mutoh, S. Takasu et al. // Cancer Prev. Res. (Phila). - 2011. - Vol. 4 (3). - P. 445-453.
291. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial / T. J. Orchard, J. Eichner, L. H. Kuller et al. // Ann. Epidemiol. - 1994. - Vol. 4(1).- P. 40-45.
292. Insulin decreases human adiponectin plasma levels / M. Mohlig, U. Wegewitz, M. Osterhoff et al. // Horm Metab Res. - 2002. - Vol. 34. - P. 655-658.
293. Insulin resistance adds prognostic information on long-term clinical outcome after acute myocardial infarction among Japanese patients with and without glucose intolerance / K. Tamita, A. Yamamuro, S. Kaji et al. // Circulation. - 2006. - Vol. 114.-P. 743.
294. Insulin resistance and atherosclerosis / J. Nigro, N. Osman, A. M. Dart et al. // Endocr. Rev. - 2006. - Vol. 27 (3). - P. 242-259.
295. Insulin Resistance Atherosclerosis Study. Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study / A. Festa, R. Jr. D’Agostino, R. P. Tracy etal. //Diabetes. - 2002. - Vol. 51. -P. 1131-1137.
296. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences /1. A. Leclercq, A. Da Silva Morais, B. Schroyen et al. // J. Hepatol. - 2007. - Vol. 47 (I). -P. 142-156.
297. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death / B. Hedblad, P. Nilsson, G. Engstrom et al. // Diabet Med. - 2002. - Vol. 19 (6). - P. 470-475.
298. Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: a prospective follow-up study / M. M. Mikkelsen, T. K. Hansen, J. Gjedsted et al. // J. Cardiothorac. Surg. - 2010. - Vol. 5. - P. 129.
299. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes / A. Patel, S. MacMahon, J. Chalmers et al. // N. Engl. J. Med. - 2008. - Vol. 358 (24).-P. 2560-2572.
300. Intensive lipid lowering with atorvastatin in patients with stable coronary disease / J. La Rosa, S. M. Grundy, D. D. Waters et al. // N. Engl. J. Med. - 2005. - Vol. 352 (14).-P. 1425-1434.
301. Intensive versus moderate lipid lowering with statins after acute coronary syndromes / С. P. Cannon, E. Braunwald, С. H. McCabe et al. // N. Engl. J. Med. - 2004. - Vol. 350 (15). - P. 1495-1504.
302. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction / A. M. Thogersen, S. Soderberg, J. H. Jansson et al. // Eur. J. Cardiovasc. Prev. Rehabil. - 2004. - Vol. 11 (I). - P. 33-40.
303. Interleukin-6 induces cellular insulin resistance in hepatocytes / J. J. Senn, P. J. Klover, I. A. Nowak et al. // Diabetes. - 2002. - Vol. 51 (12). - P. 3391-3399.
304. Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events / K. Franklin, R. J. Goldberg, F. Spencer et al. // Arch. Intern. Med. - 2004. - Vol. 164 (13). - P. 1457- 1463.
305. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a and obesity-induced insulin resistance / G. S. Hotamisligil, P. Peraldi, A. Budavari et al. // Science. - 1996. - Vol. 271. - P. 665-668. ФИО альфа и ИР
306. Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression / H. Matsui, M. Motooka, H. Koike et al. // Life Sci. - 2007. - Vol. 80. - P. 672-680.
307. Isgaard, J., Barlind, A., Johansson, I. Cardiovascular effects of ghrelin and growth hormone secretagogues / J. Isgaard, A. Barlind, I. Johansson // Cardiovasc. Hematol. Disord. Drug Targets. - 2008. - Vol. 8. - P. 133-137.
308. Ishihara, M., Kojima, S., Sakamoto, T. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era / M. Ishihara, S. Kojima, T. Sakamoto // J. Am. Heart - 2005. - Vol. 150. - P. 814-820.
309. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes / M. Y. Donath, M. Boni-Schnetzler, H. Ellingsgaard et al. // Physiology (Bethesda). - 2009 (24).-P. 325-331.
310. Jackson, M. B., Ahima, R. S. Neuroendocrine and metabolic effects of adipocyte-derived hormones / M. B. Jackson, R. S. Ahima // Clin. Sci (bond). - 2006. - HO (2). -P. 143-152.
311. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients / T. Yamazakі, J. Kishimoto, C. Ito et al. // Diabetol. Int -2011. - Vol. 2. -P. 134-140.
312. JNK and tumor necrosis factor-a mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes / M. T. Nguyen, H. Satoh, S. Favelyukis et al. // Journal of Biological Chemistry. -2005. - Vol. 280. -P. 35361-35371.
313. Jukema, J. W., van der Hoom, J. W. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy / J. W. Jukema, J. W. van der Hoom // Expert Opin on Pharmacother. - 2004. - Vol. 5. - P. 459-468.
314. Kannel, W. B., Castelli, W. P., McNamara, M. P. The coronary profile: 12- year follow-up in Framingam Study / W. B. Kannel, W. P. Castelli, M. P. McNamara // J. Occup. Med. - 1987. - Vol. 9. -P. 611-619.
315. Kaplan, N. M. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators / N. M. Kaplan // Clin. Ther. - 1996. - Vol. 18 (4). - P. 658-670.
316. Karam, J. G., Loney-Hutchinson, L., McFarlane, S. I. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators / J. G. Karam, L. Loney-Hutchinson, S. I. McFarlane // J. Cardiometab. Syndr. - 2008. - VoL 3 (I). - P. 68-69.
317. Katagiri, H., Yamada, T., Oka, Y. Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals / H. Katagiri, T. Yamada, Y. Oka // Circ Res. - 2007. - Vol. 101. - P. 27-39.
318. Katsiki, N., Banach, M. Statin use and risk of diabetes mellitus in postmenopausal women // N. Katsiki, M. Banach // Clin. Lipidol. - 2012. - Vol. 7. - P. 267-270.
319. Katsiki, N., Banach, M. Statins and the risk of diabetes: the debate / N. Katsiki, M. Banach // Arch. Intern. Med. - 2012. - Vol. 172. - P. 895-896.
320. Kershaw, E. E., Flier, J. S. Adipose tissue as an endocrine organ / E. E. Kershaw, J. S. Flier // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89 (6). - P. 2548-2556.
321. Koemer, A., Kratzsch, J., Kiess, W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come / A. Koemer, J. Kratzsch, W. Kiess // Best. Pract. Res. Clin. Endocrinol. Metab. - 2005. - Vol. 19. -525-546.
322. Koh, K. K., Sakuma, I., Quon, M. J. Differential metabolic effects of distinct statins / K. K. Koh, I. Sakuma, M. J. Quon // Atherosclerosis. - 2011. - Vol. 215. -1-8.
323. Kojima, M., Kangawa, K. Drug Insight the function of ghrelin and its potential as a multitherapeutic hormone / M. Kojima, K. Kangawa // Nature clinical practice Endocrinology and Metabolism. - 2006. - Vol. 2 (2). - P. 234-237.
324. Koltes, D., Spurlock, D. Leptin increases adipose triglyceride lipase in bovine primary adipocytes / D. Koltes, D. Spurlock // Boston Convention & Exhibition Center. - Boston. - 2013. - 156 p.
325. Kosakowski, J., Rabijewski, M., Zgliczynski, W. Ghrelin - growth hormone releasing and orexigenic hormone in men declines with age, insulin and with decrease in testosterone concentration / J. Kosakowski, M. Rabijewski, W. Zgliczynski // Neuro Endocrinol. Lett. - 2008. - Vol. 29. - P. 100-106.
326. Lam, Q. L., Lu, L.Role of leptin in immunity / Q. L. Lam, L. Lu // Cell Mol. Immunol. - 2007. - Vol. 4 (I). - P. 1-13.
327. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery / V. Haas, S. Onur, T. Paul et al. // Am. J. Clin. Nutr. -
2005. - Vol. 81 (4). - P. 889-896.
328. Leptin and coronary heart disease risk: prospective case control study of British women / D. A. Lawlor, G. Davey Smith, A. Kelly et al. // Obesity (Silver Spring). - 2007. - Vol. 15. -P. 1694-1701.
329. Leptin and coronary heart disease: prospective study and systematic review / N. Sattar, G. Wannamethee, N. Sarwar et al. // J. Am Coll. Cardiol. - 2009. - Vol. 53 (2). - P. 167-175.
330. Leptin effect on endothelial nitric oxide is mediated through Akt- endothelial nitric oxide synthase phosphorylation pathway / C. Vecchione, A. Maffei, S. Colella et al. // Diabetes. - 2002. - Vol. 51. - P. 168-173.
331. Leptin in human physiology and pathophysiology / S. M. Christos, F. Magkos, M. Brinkoetter et al. // Am J Physiol Endocrinol Metab. - 2011. - Vol. 301. - P. 567-584.
332. Leptin increase is associated with markers of the hemostatic system in obese healthy women / M. T. Guagnano, M. Romano, A. Falco et al. // J. Thromb. Haemost. - 2003. - Vol. I (I I). - P. 2330-2334.
333. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II and endothelin-1 dependent mechanisms and mediates stretch-induced hypertrophy / A. Zeidan, D. M. Purdham, V. Rajapurohitam et al. // J. Pharmacol Exp. Ther. - 2005. - Vol. 315 (3). -P. 1075-1084.
334. Leptin is associated with increased risk of myocardial infarction / S. Soderberg, B. Ahren, J. H. Jansson et al. // J. Intern. Med. - 1999. - Vol. 246. - P. 409- 418.
335. Leptin modulates the T-cell immune response and reverses starvation induced immunosuppression / G. M. Lord, G. Matarese, J. K. Howard et al. // Nature. - 1998. - Vol. 394. -P. 897-901.
336. Leptin promotes aggregation of human platelets via long form its receptor / M. Nakata, T. Yada5 N. Soejima et al. // Diabetes. - 1999. - Vol. 48. - P. 426-429.
337. Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide galanin and mediate anorexigenic leptin action / A. Laque5 Y. Zhang5
S. Gettys et al. // Am. J. Physiol. Endocrinol. Metab. - 2013. - Vol. 304 (9). - P. E999- ElOl I.
338. Leptin sensitivity in the developing rat hypothalamus / A. S. Carlo, M. Pyrski5 C. Loudes et al. // Endocrinology. - 2007. - Vol. 148 (12). - P. 6073-6082.
339. Leptin signaling in adipose tissue: role in lipid accumulation and weight gain / P. Singh5 T. E. Peterson5 F. H. Sert-Kuniyoshi et al. // Circ. Res. - 2012. - Vol. Ill (5).-P. 599-603.
340. Leptin5 not adiponectin, predicts hypertension in the Copenhagen city heart study / C. Asferg5 R. Mogelvang5 A. Flyvbjerg et al. // Am. J. Hypertens. - 2010. - Vol. 23 (3).-P. 327-333.
341. Leptinemia in persons with acute myocardial infarct / D. Stejskal5 V. Ruzicka5 J. Bartek et al. // Vnitr. Lek. - 1998. - Vol. 44. - P. 588-592.
342. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study / C. Couillard5 B. Lamarche5 P. Mauriege et al. // Diabetes Care. - 1998. - Vol. 21. - P.782-786.
343. Libby5 P., Nahrendorf5 M., Weissleder R. Molecular imaging of atherosclerosis: a progress report / P. Libby5 M. Nahrendorf5 R. Weissleder // Tex. Heart Inst. J. - 2010. - Vol. 37 (3). - P. 324-327.
344. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study / J. W. Yamell5 P. M. Sweetnam5 A. Rumley et al. // Arterioscler. Thromb. Vase. Biol. - 2000. - Vol. 20. - P. 271-279.
345. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease / V. D. de Mello5 M. Lankinen5 U. Schwab et al. // Diabetologia. - 2009. - Vol. 52 (12). - P. 2612-2615.
346. Lipids, blood pressure, kidney - what was new in 2011? / M. Barylski, J. Mayszko, J. Rysz et al. // Arch. Med. Sci. - 2011. - Vol. 7. - P. 1055-1066.
347. Lipolysis and the integrated physiology of lipid energymetabolism / S. Wang, K. G. Soni, M. Semache et al. // Molecular Genetics and Metabolism. - 2008. - Vol. 95. -P. 117-126.
348. Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-kB / D. Cai, M. Yuan, D. F. Frantz et al. // Nature Medicine. - 2005. - Vol. 11.-P. 183-190.
349. Long-term effects of central leptin and resistin on body weight, insulin resistance, and P-cell function and mass by the modulation of hypothalamic leptin and insulin signaling / S. Park, S. M. Hong, S. R. Sung et al. // Endocrinology. - 2008. - Vol. 149 (2). -P. 445-454.
350. Lopaschuk, G. D., Clifford, D. L., Folmes, C. Cardiac energy metabolism in obesity / G. D. Lopaschuk, D. L. Clifford, C.Folmes // Circulation Research. - 2007. -Vol. 101.-P. 335-347.
351. Loss of leptin actions in obesity: two concepts with cardiovascular implications / A. L. Mark, M. L. Correia, K. Rahmouni et al. // Clin. Exp. Hypertens. - 2004. - Vol. 26. -P. 629-636.
352. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity / T. F. McGuire, X. Q. Xu, S. J. Corey et al. // Biochem. Biophys. Res. Commun. - 1994. - Vol. 204. - P. 399-406.
353. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses / J. Danesh, P. Whincup, M. Walker et al. // BMJ. - 2000. - Vol. 321.-P. 199-204.
354. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes / S. M. Poykko, E. Kellokoski, S. Horkko et al. // Diabetes. - 2003. - Vol. 52. - P. 2546-2553.
355. Macrophages in human visceral adipose tissue: increase daccumulation in obesity and a source of resistin and visfatin / C. A. Curat, V. Wegner, C. Sengenes et al. // Diabetologia. - 2006. - Vol. 49. - P. 744-747.
356. Maingrette, F., Renier, G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C / F. Maingrette, G. Renier // Diabetes. - 2003. - Vol. 52 (8). - P. 2121-2128.
357. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation / F. V. Werf, J. Bax, A. Betriu et al. // Eur. Heart J. - 2008. - Vol. 29. -P. 2909-2945.
358. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) / S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al. // Diabetologia. - 2012. - Vol. 55. - P. 1577-1596.
359. Martin, S. S., Qasim, A., Reilly, M. P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease / S. S. Martin, A. Qasim, M. P. Reilly // J. Am. Coll. Cardiol. - 2008. - Vol. 52 (15). - P. 1201-1210.
360. Matsubara, M., Maruoka, S., Katayose, S. Decreased plasma adiponectin concentrations in women with dyslipidemia / M. Matsubara, S. Maruoka, S Katayose // J. Clin. Enodcrinol. Metab. - 2002. - Vol. 87 (6). - P. 2764-2769.
361. Mattu, H. S., Randeva, H. S. Role of adipokines in cardiovascular disease / H. S. Mattu, H. S. Randeva // J. Endocrinol. - 2013 - Vol. 216 (I) - P. 17-36.
362. Meams, В. M. Statins and risk of diabetes mellitus / B. M. Mearns // Nat. Rev. Cardiol. - 2012. - Vol. 9. - P. 552.
363. Mertens, I., Van Gaal, L. F. Obesity, haemostasis and the fibrinolytic system /1. Mertens, L. F Van Gaal // Obes. Rev. - 2002. - Vol. 3 (2). - P. 85-101.
364. Meta-Analysis of Impact of Different Types and Doses of Statins on New- Onset Diabetes Mellitus / E. P. Navarese, A. Buffon, F. Andreotti et al. // Am. J. Cardiol.-2013.-Vol. lll.-P. 1123-1130.
365. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study / N. Sattar, A. Gaw, O. Scherbakova et al. // Circulation. - 2003. - Vol. 108. - P. 414- 419.
366. Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states / R. Rabasa-Lhoret, J. P. Bastard, V. Jan et al. // Journal of Clinical Endocrinology and Metabolism. - 2003. - Vol. 88. - P. 4917-4923.
367. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways / M. Guha, W. Bai, J. L. Nadler et al // J Biol Chem. - 2000. - Vol. 275 (23). -P. 17728-17739.
368. Moller, D. E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes / D. E. Moller // Trends Endocrinol Metab. - 2000. - Vol. 11 (6).-P.212-217.
369. Mori, K. Kidney produces a novel acylated peptide, ghrelin / K. Mori // FEBS Lett. -2003. - Vol. 486. -P. 213-216.
370. Myocardial Fatty Acid Metabolism in Health and Disease / G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes et al // Physiol. Rev. - 2010. - Vol. 90. - P. 207-258.
371. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents / H. Tunstall-Pedoe, K. Kuulasmaa, P. Amouyel et al. // Circulation. - 1994. - Vol. 90. - P. 583-612.
372. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats / C. Berthonneche, T. Sulpice, F. Boucher et al. // Am J Physiol Heart Circ Physiol. - 2004. - Vol. 287. - P. 340-350.
373. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics / A. Wada, H. Yokoo, T. Yanagita et al. // J. Pharmacol. Sci. - 2005. - Vol. 99.-P. 128-143.
374. Newcomer, M. E., Ong, D. E. Plasma retinol binding protein: structure and function of the prototypic lipocalin / M. E. Newcomer, D. E. Ong // Biochimica et Biophysica Acta. - 2000. - Vol. 1482. - P. 57-64.
375. Newly diagnosed and previously known diabetes mellitus and I-year outcomes of acute myocardial infarction / D. Aguilar, S. D. Solomon, L. Kober et al. // Circulation. - 2004. - Vol. 110 (12). - P. 1572-1578.
376. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice / A. Trion, M. P. de Maat, J. W. Jukema et al. // Arterioscler. Thromb. Vase. Biol. - 2005. - Vol. 25. - P. 1635-1640.
377. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fe fusion protein in obese insulin- resistant patients / N. Paquot, M. J. Castillo, P. J. Lefebvre et al. // J. Clin. Endocrinol. Metab. - 2000. - Vol. 85. -P. 1316-1319.
378. Non-high-density lipoprotein cholesterol levels vs apoliprotein B or Apo B/Apo Al and risk of coronary heart disease among apparently healthy men and women / J. S. Rana, В. M. Sondermeijer, B. J. Arsenault et al. // Circulation. - 2011. - Vol. 124. -P. Al3846.
379. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study / J. F. Keaney, M. G. Larson, R. S. Vasan et al. // Arterioscler. Thromb. Vase. Biol. - 2003. - Vol. 23 (3). - P. 434-439.
380. Obesity, inflammation and acute myocardial infarction - expression of leptin, IL-6 and high sensitivity-CRP in Chennai based population / K. Rajendran, N. Devarajan, M. Ganesan et al. // Thromb. J. - 2012. - Vol. 10 (I). - P. 13.
381. Okamoto, Y., Arita, Y., Nishida, M. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls / Y. Okamoto, Y. Arita, M. Nishida // Horm Metab Res. - 2000. - Vol. 32. - P. 47-50.
382. Oliver, M. F. Sudden cardiac death: the lost fatty acid hypothesis / M. F. Oliver // Q. J. Med. - 2006. - Vol. 99 (10). - P. 701-710.
383. Oliver, M. F., Opie, L. H. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias / M. F. Oliver, L. H. Opie // Lancet. - 1994. - Vol. 343. - P.155-158.
384. Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair / M. Gwechenberger, D. Moertl, R .Pacher et al. // Croat Med J. - 2004. - Vol. 45.-P. 149-157.
385. Opie, L. H. Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia / L. H. Opie // Circulation. -
2008. - Vol. 117. - P. 2172-2177.
386. Opie, L. H., Knuuti, J. The adrenergic-fatty acid load in heat failure / L. H. Opie, J. Knuuti // J. Am. Coll. Cardiol. - 2009. - Vol. 54. - P. 1637-1646.
387. Oral, E. A., Burant, C. Leptin and insulin resistance: good, bad, or still unclear? / E. A. Oral, C. Burant // Am. J. Physiol. Endocrinol. Metab. - 2009. - Vol. 296 (2).-P. E394-E395.
388. Pair feeding-mediated changes in metabolism: stress response and pathophysiology in insulin-resistant, atherosclerosis-prone JCR: LA-cp rats / J. C. Russell, S. D. Proctor, S. E. Kelly et al. // Am. J. Physiol. Endocrinol. Metab. - 2008. - Vol. 294 (6). -P. E1078-El 087.
389. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity / Y. Arita, S. Kihara, N. Ouchi et al. // Biochem. Biophys. Res. Commun. - 1999. - Vol. 257. -P. 79-83.
390. Pedersen, B. K. IL-6 signalling in exercise and disease / В. K. Pedersen // Biochem. Soc. Trans. - 2007. - Vol. 35 (5). - P. 1295-1297.
391. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis / T. Naruko, M. Veda., S. Ehara et al. // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2006. - Vol. 26. - P.833- 877.
392. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action / V. Aguirre, E. D. Werner, J. Giraud et al. // Journal of Biological Chemistry. - 2002. - Vol. 277. - P. 1531-1537.
393. Physical activity and hemostatic and inflammatory variables in elderly men / S. G. Wannamethee, G. D. Lowe, P. H. Whincup et al. // Circulation. - 2002. - Vol. 105.-P. 1785-1790.
394. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo / J. A. Cases, I. Gabriely, X. H. Ma et al. // Diabetes. - 2001. - Vol. 50 (2). - P. 348-352.
395. Piestrzeniewicz, K., Luczak, K., Goch, H. Value of blood adipose tissue hormones concentration - adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in I-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction / K. Piestrzeniewicz, K. Luczak, H. Goch // Neuro. Endocrinol. Lett. - 2008. - Vol. 29 (4). - P. 581-588.
396. Pischon, T. Association between dietary factors and plasma adiponectin concentrations in men / T. Pischon // Am J Clin Nutr. - 2005. - Vol. 81. - P. 780-786.
397. Pittas, A. G., Joseph, N. A. Adipocytokines and insulin resistance / A. G. Pittas, N. A. Joseph // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89 (2). - P. 447-452.
398. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans / N. Stefan, B. Vozarova, T. Funahashi et al. // Diabetes. - 2002. - Vol. 51. - P. 1884-1888.
399. Plasma adiponectin levels and risk of myocardial infarction in men / T. Pischon, C. J. Girman, G. S. Hotamisligil et al. // JAMA. - 2004. - Vol. 291 (14). - P. 1730-1737.
400. Plasma concentration of a novel adipose specific protein adiponectin in type 2 diabetic patients / K. Hotta, T. Funahashi, Y. Arita et al. // Arterioscler Thromb Vase Biol. - 2000. - Vol. 20. - P.1595-1599.
401. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men / P. M. Ridker, N. Rifai, M. J. Stampfer et al. // Circulation. - 2000. - Vol. 101 (15). -P. 1767-1772.
402. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study / M. Pirro, P. Mauriege, A. Tchemof et al. // Atherosclerosis. - 2002. - Vol. 160 (2). - P. 377-384.
403. Plasma insulin, leptin and soluble TNF receptors levels in relation to obesity related atherogenic and thrombogenic cardiovascular disease risk factors among men / N. F. Chu, D. Spiegelman, G. S. Hotamisligil et al. // Atherosclerosis. - 2001. - Vol. 157 (2). -P. 495-503.
404. Plasma leptin and prognosis in patients with established coronary atherosclerosis / R. Wolk, P. Berger, R. J. Lennon et al. // J. Am Coll. Cardiol. - 2004. -Vol. 44.-P. 1819-1824.
405. Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronaiy Prevention Study (WOSCOPS) / A. M. Wallace, A. D. McMahon,
C. J. Packard et al. // Circulation. - 2001. - Vol. 104 (25). - P. 3052-3056.
406. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes / M. P. Reilly, N. Iqbal, M. Schutta et al. // J. Clin. Endocrinol. Metab. - 2004.
- Vol. 89 (8). - P. 3872-3878.
407. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm in cortisol and leptin secretion / S. R. Bomstein, J. Licinio, R. Tauchnitz et al. // J. Clin. Endocrinol. Metab. - 1998. - Vol. 83. - P. 280-283.
408. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance / J. M. Fernandez-Real, M. Broch, W. Ricart et al. // Diabetes. - 1998. -Vol. 47. -P. 1757-1762.
409. Plasma levels of the soluble fraction of tumor necrosis factor-а receptors I and 2 are independent determinants of total and LDL-cholesterol concentrations in healthy subjects / J. M. Femandez-Real, C. Gutierrez, W. Ricart et al. // Atherosclerosis.
- 1999. - Vol. 146. -P. 321-327.
410. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study /
В. Wiman, Т. Andersson, J. Hallqvist et al. // Arterioscler. Thromb. Vase. Biol. - 2000. - Vol. 20 (8).-P. 2019-2023.
411. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus / B. S. Youn5 K. Y. Yu5 H. J. Park et al. // J. Clin. Endocrinol. Metab. -2004. - Vol. 89 (I). -P. 150-156.
412. Plasma resistin levels and risk of myocardial infarction and ischemic stroke / C. Weikert5 S. Westphal5 K. Berger et al. // J. Clin. Endocrinol. Metab. - 2008. - Vol. 93 (7).-P. 2647-2653.
413. Plasma tumour necrosis factor-а and early carotid atherosclerosis in healthy middle-aged men / T. Skoog5 W. Dichtl5 S. Boquist et al. // Eur. Heart. J. - 2002. - Vol. 23.-P. 376-383.
414. Plasminogen activator inhibitor I5 transforming growth factor-betal, and BMI are closely associated in human adipose tissue during morbid obesity / M. C. Alessi5 D. Bastelica5 P. Morange et al. // Diabetes. - 2000. - Vol. 49 (8). - P. 1374- 1380.
415. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with avb3 integrin for vitronectin binding / R. Lopez-Alemany5 J. M. Redondo5 Y. Nagamine et al. // J. Eur. Biochem. - 2003. - Vol. 270. - P. 814-821.
416. Plasminogen activator inhibitor-1 modulates adipocyte differentiation / X. Liang5 T. Kanjanabuch5 S. L.Mao et al. // J. Physiol. Endocrinol. Metab. - 2006. - Vol. 290. -P. 103-113.
417. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistence and vascular risk /1. Juhan-Vague5 M. C. Alessi5 A. Mavri et al. // J. Thromb. Haemost. -2003.-Vol. l.-P. 1575- 1579.
418. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes / R. Krysiak5 A. Gdula-Dymek5 R. Bachowski et al. // Diabetes Care. - 2010. - Vol. 33 (10). - P. 2266-2270.
419. Positional cloning of the mouse obese gene and its human homologue/ Y. Zhang5 R. Proenca5 M. Maffei et al. // Nature. - 1994. - Vol. 372. - P. 425-432.
420. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/ premeal glycemia/1. Raz, A. Ceriello, P. W. Wilson et al. // Diabetes Care. - 2011. - Vol. 34. - P. 1511-1513.
421. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study / F. Cavalot, A. Pagliarino, M. Valle et al. // Diabetes Care. - 2011. - Vol. 34. - P. 2237-2243.
422. Potential role of adipocytokine leptin in acute coronary syndrome / L. Dubey, H. S. Zeng, H. J. Wang et al. // Asian. Cardiovasc. Thorac. Ann. - 2008. - Vol. 16 (2).-P. 124-128.
423. PPAR gamma ligands increase expression and plasma concentrations of adiponectin an adipose derived protein / N. Maeda, M. Takahashi, T. Funahashi et al. // Diabetes. - 2001. - Vol. 50. - P. 2094-2099.
424. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study / D. J. Freeman, J. Norrie, N. Sattar et al. // Circulation. - 2001. - Vol. 103 (3). - P. 357-362.
425. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. С-reactive protein levels and outcomes after statin therapy / P. Ridker, C. Cannon, D. Morrow et al. // N. Engl. J. Med. - 2005. - Vol. 352 (I). - P. 20-28.
426. Pre- and post-translational negative effect of b-adrenoreceptor agonists on adiponectin secretion: in vitro and in vivo studies / M. L. Delporte, T. Funahashi, M. Takahashi et al. // Biochem J. - 2002. - Vol. 367. - P. 677-685.
427. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score / A. Halkin, M. Singh, E. Nikolsky et al. // J. Am. Coll. Cardiol. - 2005. - Vol. 45 (9). - P. 1397-1405.
428. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) / К. A. Fox, O. H. Dabbous, R. J. Goldberg et al. // BMJ. - 2006. - Vol. 333 (7578).-P. 1091.
429. Predictors of hospital mortality in the Global Registry of Acute Coronary Events / С. B. Granger, R. J. Goldberg, О. M. Dabbous et. al. // Archives Internal Medicine. - 2003. - Vol. 163 (19). -P. 2345-2353.
430. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials / D. D. Waters, J. E. Ho, D. A. DeMicco et al. //J. Am. Coll. Cardiol. - 2011. - Vol. 57. -P. 1535-1545.
431. Preiss, D., Sattar, N. Statins and the risk of new-onset diabetes: a review of recent evidence / D. Preiss, N. Sattar // Curr. Opin. Lipidol. - 2011. - Vol. 22. -P. 460- 466.
432. Prevalence of conventional risk factors in patients with coronary heart disease / U. N. Khot, M. B. Khot, C. T. Bajzer et al. // JAMA. - 2003. - Vol. 290 (7). - P. 898-904.
433. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels / Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group // N. Engl. J. Med. - 1998. - Vol. 339. -P. 1349-1357.
434. Prevention of obesity and insulin resistence in mice lacking plasminogen activator inhibitor-1 / L. J. Ma, S. L. Mao, K. L. Taylor et al. // Diabetes. - 2004. - Vol. 53.-P. 336-346.
435. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study / J. R. Downs, M. Clearfield, S. Weis et al. //JAMA. - 1998. - Vol. 279 (20). -P. 1615-1622.
436. Protection from obesity-induced insulin resistance in mice lacking TNF-a function / K. T. Uysal, S. M. Wiesbrock, M. W. Marino et al. // Nature. - 1997. - Vol. 389.-P.610-614.
437. Protein phosphatase I (PP-I) dependent inhibition of insulin secretion by leptin in INS-1 pancreatic cells and human pancreatic islets / P. Kuehnen, K. Laubner, K. Raile et al. // Endocrinology. - 2011. - Vol. 152 (5). -P. 1800-1808.
438. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans / A. Katz, S. Nambi, K. Mather et al. // J. Clin. Endocrinol. Metab. -2000. - Vol. 85. -P. 2402-2410.
439. QUICKI Is Useful for Following Improvements in Insulin Sensitivity after Therapy in Patients with Type 2 Diabetes Mellitus / A. Katsuki, S.Yasuhiro, C. G. Esteban et al. // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87. - P. 2906-2908.
440. Race and gender differences in C-reactive protein levels / A. Khera, D. K. McGuire, S. A. Murphy et al. // J. Am. Coll. Cardiol. - 2005. - Vol. 46. - P. 464-469.
441. Rajapurohitam V., Javadov S. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1 / V. Rajapurohitam, S. Javadov // J. Mol. Cell. Cardiol. - 2006. - Vol. 41 (2). - P. 74-265.
442. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) / T. R. Pedersen, J. Kjekshus, K. Berg et al. // Atheroscler. Suppl. - 2004. - Vol. 5 (3). - P. 81-87.
443. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at I year / K. Malmberg, L. Ryden, S. Efendic et al. // J. Am Coll. Cardiol. - 1995. - Vol. 26. -P. 57-65.
444. Rat heart is a site of leptin production and action / D. M. Purdham, M. X. Zou, V. Rajapurohitam et al. // Am. J. Physiol. Heart Circ. Physiol. - 2004. - Vol. 287. -P. H2877-H2884.
445. Ray, K. K., Cannon, С. P. The potential relevance of the multiple lipid- independent (pleiotropic) effects of statins in the management of acute coronary syndromes / K. K. Ray, С. P. Cannon // J. Am. Coll. Cardiol. - 2005. - Vol. 46 (8). - P. 1425-1433.
446. RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes / C. Erikstmp, 0. H. Mortensen, A. R. Nielsen et al. // Diabetes, Obesity & Metabolism. - 2009. - Vol. 11. -P. 204-212.
447. Reaven, G. M. Role of insulin resistance in human disease (syndrome X): an expanded definition / G. M. Reaven // Annu Rev. Med. - 1993. - Vol. 44. - P. 121- 131.
448. Recombinant leptin promotes atherosclerosis and thrombosis inapolipoprotein E-defi cient mice / P. F. Bodary, S. Gu, Y. Shen et al. // Arterioscler. Thromb. Vase. Biol. - 2005. - Vol. 25. - P. 119-122.
449. Reduced tyrosine kinase activity of the insulin receptor in obesitydiabetes /
G. S. Hotamisligil, A. Budavari, D. Murray et al. // J. Clin. Invest. - 1994. - Vol. 94. - P. 1543-1549.
450. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial / P. M. Ridker, E. Danielson, F. A. Fonseca et al. // Lancet. - 2009. - Vol. 373 (9670). - P. 1175-1182.
451. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients / H. Mabuchi, T. Higashikata, M. Kawasliiri et al. // J. Atheroscler. Thromb. -2005. - Vol. 12 (2). -P. 111-119.
452. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans / J. M. Bruun, A. S. Lihn, C. Verdich et al. // Am J. Physiol. Endocrinol. Metab. -2003. - Vol. 285 (3). -P. E527-E533.
453. Regulation of fasted blood glucose by resistin / R. R. Banerjee, S. M. Rangwala, J. S. Shapiro et al. // Science. - 2004. - Vol. 303 (5661). - P. 1195-1198.
454. Relation between retinol, retinolbinding protein 4, transthyretin and carotid intima media thickness / T. Bobbert, J. Raila, F. Schwarz et al. // Atherosclerosis. - 2010.-Vol. 213.-P. 549-551.
455. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population / J. Sierra-Johnson, A. Romero- Corral, F. Lopez-Jimenez et al. // Am. J. Cardiol. - 2007. - Vol. 100 (2). - P. 234-239.
456. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients / T. Skurk, V. van Harmelen, Y. M. Lee et al. // Horm. Metab. Res. - 2002. - Vol. 34 (11-12). - P. 659-663.
457. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes / P. Calabro, D. Chang, J. T. Willerson et al. // J. Am Coll. Cardiol. - 2005. - Vol. 46. -P. 1112-1113.
458. Ren, J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function / J. Ren // J. Endocrinol. - 2004. - Vol. 181. - P. 1-10.
459. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia / reperfusion / N. G. Frangogiannis, M. L. Lindsey, L. H. Michael et al. // Circulation. - 1998. - Vol. 7. - P. 699-710.
460. Residual beta cell function in newly diagnosed type I diabetes after treatment with atorvastatin: the Randomized DIATOR Trial / S. Martin, C. Herder, N.
C. Schloot et al. // PLoS One. - 2011. - Vol. 6. - P. ЄІ7554.
461. Resistin is an inflammatory marker of atherosclerosis in humans / M. P. Reilly, M. Lehrke, M. L. Wolfe et al. // Circulation. - 2005. - Vol. Ill (7). - P. 932- 939.
462. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis / H. S. Jung, К. H. Park, Y. M. Cho et al. // Cardiovasc. Res. - 2006. - Vol. 69(1).-P. 76-85.
463. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction / S. Verma, S. H. Li, C. H. Wang et al. // Circulation. - 2003. - Vol. 108 (6). - P. 736-740.
464. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity / J. Vendrell, M. Broch, N. Vilarrasa et al. // Obes. Res. - 2004. -Vol. 12 (6).-P. 962-971.
465. Resistin, an adipokine with potent proinflammatory properties / M. Bokarewa, I. Nagaev, L. Dahlberg et al. // J. Immunol. - 2005. - Vol. 174 (9). - P. 5789-5795.
466. Retinol binding protein 4, low birth weight-related insulin resistance and hormonal contraception / A. Zugaro, C. Pandolfi, A. Barbonetti et al. // Endocrine. - 2007.-Vol. 32.-R 166-169.
467. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women / Z. Mallat, T. Simon, J. Benessiano et al. // Journal of Clinical Endocrinology and Metabolism. - 2009. - Vol. 94. - P. 255-260.
468. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkb / M. Yuan, N. Konstantopoulos, J. Lee et al. // Science. - 2001. - Vol. 293. -P. 1673-1677.
469. Review: leptin gene expression in the placenta - regulation of a keyhormone in trophoblast proliferation and survival / J. L. Maymo, A. P. Perez, Y. Gambino et al. // Placenta. - 2011. - Vol. 32 (2). - P. S146-S153.
470. Ridker, P. M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention / P. M. Ridker // Circulation. - 2003. - Vol. 107 (3). - P. 363-369.
471. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis / D. Preiss, S. R. Seshasai, P. Welsh et al. // JAMA. - 2011. - Vol. 305. - P. 2556-2564.
472. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide / P. A. Kavsak, D. T. Ко, A. M. Newman et al. // Clinical Chemistry. - 2007. - Vol. 53 (12).-P.2112-2118.
473. Rizzo, M., Bemeis, K. Low-density lipoprotein size and cardiovascular risk assessment / M. Rizzo, K. Berneis // QJM. - 2006. - Vol. 99. - P. 1-14.
474. Role of baseline leptin and ghrelin levels on body weight and fat mass changes after an energy-restricted diet intervention in obese women: effects on energy metabolism /1. Labayen, F. B. Ortega, J. R. Ruiz et al. // J. Clin. Endocrinol. Metab. - 2011. - Vol. 96 (6). -P. E996-E1000.
475. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? / K. Reifenberg, H. A. Lehr, D. Baskal et al. // Arterioscler. Thromb. Vase. Biol. -2005. - Vol. 25. -P. 1641-1646.
476. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain / S. E. Kahn, S. M. Haffner, G. Viberti et al. // Diabetes Care. - 2010. - Vol. 33. - P. 177-183.
477. Rosuvastatin in older patients with systolic heart failure / J. Kjekshus, E. Apetrei, V. Barrios et al. // N. Engl. J. Med. - 2007. - Vol. 357. - P. 2248-2261.
478. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein / P. M. Ridker, E. Danielson, F. A. Fonseca et al. / N. Engl. J. Med. - 2008. - Vol. 359. -P. 2195-2207.
479. Sack, M. N., Smith, R. M., Opie, L. H. Tumor necrosis factor in myocardial hypertrophy and ischaemia - an anti-apoptotic perspective / M. N. Sack, R. M. Smith, L. H. Opie // Cardiovasc. Res. - 2000. - Vol. 3. - P. 688-695.
480. Sampson, U. K., Linton, M. F., Fazio, S. Are statins diabetogenic? / U. K. Sampson, M. F. Linton, S. Fazio // Curr. Opin. Cardiol. - 2011. - Vol. 26 (4). - P. 342- 347.
481. Sattar, N., Taskinen, M. R. Statins are diabetogenic - myth or reality? / N. Sattar, M. R. Taskinen // Atheroscler. Suppl. - 2012. - Vol. 13. - P. 1-10.
482. Sell, H., Eckel, J. Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-alpha / H. Sell, J. Eckel // Diabetologia. - 2007. - Vol. 50. -P. 2221-2223.
483. Serine phosphorylation of insulin receptor substrate I by inhibitor кВ kinase complex / Z. Gao, D. Hwang, F. Bataille et al. // Journal of Biological Chemistry. - 2002. - Vol. 211.-V. 48115-48121.
484. Serum leptin and myocardial infarction in hypertension / S. M. Wallerstedt, A. L. Eriksson, A. Niklason et al. // Blood Press. - 2004. - Vol. 13 (4). - P. 243-246.
485. Serum resistin concentrations and risk of new onset heart failure in older persons: the Health, Aging and Body Composition (Health ABC) Study / J. Butler, A.
Kalogeropoulos, V. Georgiopoulou et al. // Harris for the Health ABC Study. Arterioscler. Thromb. Vase. Biol. -2009. - Vol. 29 (7). -P. 1144-1149.
486. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes / Q. Yang, T. E. Graham, N. Mody et al. // Nature. - 2005. - Vol. 436. -P. 356-362.
487. Seth, S. M., Atif, Q., Muredach, P. R. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease / S. M. Seth, Q. Atif, P. R. Muredach // J. Am. Coll. Cardiol. - 2008. - Vol. 52 (15). - P. 1201-1210.
488. Seufert, J. Leptin effects on pancreatic p-cell gene expression and function / J. Seufert // Diabetes. - 2004. - Vol. 53 (I). - P. 152-158.
489. Shankar, A., Xiao, J. Positive relationship between plasma leptin level and hypertension / A. Shankar, J. Xiao // Hypertension. - 2010. - Vol. 56 (4). - P. 623-628.
490. Sherwin, R., Jastreboff, A. M. Year in diabetes 2012: The diabetes tsunami / R. Sherwin, A. M. Jastreboff // J. Clin. Endocrinol. Metab. - 2012. - Vol. 97. - P. 4293-4301.
491. Sidhu, J. S., Cowan, D., Kaski, J. C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, Creactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients / J. S. Sidhu, D. Cowan, J. C. Kaski // J. Am. Coll. Cardiol. - 2003. - Vol. 42.-P. 1757-1763.
492. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin / L. Li, J. C. Mamputu, N. Wiemsperger et al. // Diabetes. - 2005. - Vol. 54. - P. 2227-2234.
493. Significance of an index of insulin resistance in non-diabetic patients with impaired fasting glucose with acute myocardial infarction and its correlation to short term outcome / D. P. Sinha, S. Ahmed, A. K. Baneeijee et al. // Indian Heart J. - 2009. -Vol. 61 (I).-P. 40-43.
494. Significance of an index of insulin resistance on admission in non-diabetic patients with acute coronary syndromes // P. J. Stubbs, J. Alaghband-Zadeh, J. F. Laycock et at. // Heart. - 1999. - Vol. 82. - P. 443-447.
495. Simsek, S., Schalkwijk, C. G., Wolffenbuttel, В. H. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes - the CORALL study / S. Simsek, C. G. Schalkwijk, B. H. Wolffenbuttel // Diabet. Med. - 2012. - Vol. 29. - P. 628-631.
496. SOCS-I and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRSl and IRS2 / L. Rui, M. Yuan, D. Frantz et al. // Journal of Biological Chemistry. - 2002. - Vol. 277. - P. 42394-42398.
497. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-a in the adipose tissue of obese mice / Emanuelli B., Peraldi P., Filloux C. et al. // Journal of Biological Chemistry. - 2001. - Vol. 276. - P. 47944-47949.
498. Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction / Y. Monden, T. Kubota,
T. Tsutsumi et al. // Cardiovasc Res. - 2007. - Vol. 73. - P. 794-805.
499. Soluble TNFa receptors in young obese subjects with normal and impaired glucose tolerance / S. Dzienis-Straczkowska, M. Straczkowski, M. Szelachowska et al. // Diabetes Care. - 2003. - Vol. 26. - P. 875-880.
500. Staiger, H., Tschritter, O., Kausch, C. Human serum adiponectin levels are not under shot-term negative control by free fatty acids in vivo / H. Staiger, O. Tschritter, C. Kausch// Horm. Metab. Res. - 2002. - Vol. 34. -P. 601-603.
501. Statin discontinuation: counterbalancing the benefits with the potential risks / K. I. Paraskevas, S. Koupidis, F. Gentimi et al. // Arch. Med. Sci. - 2011. - Vol. 7. - P. 1076-1077.
502. Statin Therapy and New-Onset Diabetes: Molecular Mechanisms and Clinical Relevance / M. Banach, M. Malodobra-Mazur, A. Gluba et al. // Curr. Pharm. Des. - 2013. - Vol. 19 (27). - P. 4904-4912.
503. Statin therapy and risk of developing type 2 diabetes: a meta-analysis / S. N. Rajpathak, D. J. Kumbhani, J. Crandall et al. // Diabetes Care. - 2009. - Vol. 32 (10).-P. 1924-1929.
504. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? / Y. Ma, A. Culver, J. Rossouw et al. // Ther. Adv. Cardiovasc. Dis. -2013.-Vol. 7.-P.41-44.
505. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative / A. L. Culver, I. S. Ockene, R. Balasubramanian et al. // Arch. Intern. Med. - 2012. - Vol. 172. - P. 144-152.
506. Statins and New-Onset Diabetes / M. Barylski, D. Nikolic, M. Banach et al. // Current Pharmaceutical Design. - 2013. - Vol. 19. - P. 1-8.
507. Statins and new-onset diabetes: a retrospective longitudinal cohort study / T. Ma, L. Tien, C. L. Fang et al. // Clin. Ther. - 2012. - Vol. 34. - P. 1977-1983.
508. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials / N. Sattar, D. Preiss, H. M. Murray et al. // Lancet. - 2010. - Vol. 375. -735-742.
509. Statins, risk of diabetes, and implications on outcomes in the general population / K. L. Wang, C. J. Liu, T. F. Chao et al. // J. Am. Coll. Cardiol. - 2012. - Vol. 60.-P. 1231-1238.
510. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial) / P. H. Jones, M. H. Davidson, E. A. Stein et al. // Am. J. Cardiol. - 2003. - Vol. 92 (2) - P. 152-160.
511. Steppan, C. M., Lazar, M. A. Resistin and obesity-associated insulin resistance / С. M. Steppan, M. A. Lazar // Trends in Endocrinology and Metabolism. -
2002. -Vol. 13(1).-P. 18-25.
512. Sundell, J. Obesity and diabetes as risk factors for coronary artery disease: from the epidemiological aspect to the initial vascular mechanisms / J. Sundell // Diabetes Obes. Metab. - 2005. - Vol. 7. - P. 9-20.
513. Synthetic peroxisome proliferator-activated receptorgamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients / W. S. Yang, C. Y. Jeng, T. J. Wu et al. // Diabetes Care. - 2002. - Vol. 25. - P. 376-380.
514. Taegtmeyer, H., McNulty, P., Young, M. E. Adaptation and Maladaptation of the Heart in Diabetes: Part I, General Concepts / H. Taegtmeyer, P. McNulty, M. E. Young // Circulation. - 2002. - Vol. 105. - P.1727-1733
515. Takaya, K. Ghrelin strongly stimulates growth hormone release in humans / K. Takaya // J. Clin. Endocrinol. Metab. - 2000. - Vol. 85. - P. 4908-4911.
516. Tansey, M. J., Opie, L. H. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction / M. J. Tansey, L. H. Opie // Lancet. - 1983. - Vol. 23 (8347). - P. 419-422.
517. Tenenbaum, A., Fisman, E. Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? / A. Tenenbaum, E. Z. Fisman // Cardiovasc. Diabetol. - 2012. - Vol. 11. - P. 140.
518. Teramoto, T. Pitavastatin: clinical effects from the LIVES Study / T. Teramoto // Atheroscler. Suppl. - 2011. - Vol. 12. - P. 285-2258.
519. Testosteron administration suppresses adiponectin levels in men / S. T. Page, K. L. Herbst, J. K. Amory et al. // J Androl. - 2005. - Vol. 26. - P. 85-92.
520. The association of intensive statin therapy on long-term risks of cardiovascular events and diabetes following acute myocardial infarction (abstract) / A. Yousef, J. V. Tu, J. Wang et al. // Circulation. - 2012. - Vol. 125. - P. e859.
521. The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? // Diabetes Care. - 2003. - Vol. 26. - P. 688-696.
522. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia / Diabetes Atorvastin Lipid Intervention (DALI) Study Group // Diabetes Care. - 2001. - Vol. 24 (8). - P. 1335-1341.
523. The effect of early, intensive statin therapy on acute coronary syndrome /
E. Hulten, J. L. Jackson, K. Douglas et al. // Arch. Intern. Med. - 2006 - Vol. 166 (17). -P. 1814-1821.
524. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetes subjects / J. G. Yu, S. Javorschi, A. L. Hevener et al. // Diabetes. - 2002. - Vol. 51. - P. 2968-2974.
525. The emerging role of ITOL in glucose metabolism / B. G. Drew, K. A. Rye, S. J Duffy et al. // Nat. Rev. Endocrinol. - 2012. - Vol. 8. - P. 237-245.
526. The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity / T. Yamauchi, J. Kamon, H. Waki et al. // Nat Med. -2001.-Vol. 7. -P. 941-946.
527. The hormone resistin links obesity to diabetes / C. M. Steppan, S. T. Bailey, S. Bhat et al. // Nature. - 2001. - Vol. 409. - P. 307-312.
528. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy / A. Bielecka-Dabrowa, J.
H. Goch, D. P. Mikhailidis et al. // Med. Sci. Monit. - 2009. - Vol. 15 (12). - P. MS12- MS23.
529. The kidney as a second site of human C-reactive protein formation in vivo / W. J. Jabs, B. A. Logering, P. Gerke et al. // Eur J Immunol. - 2003. - Vol. 33. - P. 152-161.
530. The Plasminogen Activator Inhibitor-1 -675 4G/5G genotype influences the risk of Myocardial Infarction associated with elevated plasma proinsulin/insulin levels in men from Europe /1. Juhan-Vague, P. E. Morange, C. Frere et al. // J. Thromb. Haemost. - 2003. - Vol. I. - P. 2322-2329.
531. The roles of IL-6, IL-10 and IL-IRA in obesity and insulin resistance in African-Americans / B. A. Charles, A. Doumatey, H. Huang et al. // J. Clin. Endocrinol. Metab. -2011. - Vol. 96 (12). -P. E2018-E2022.
532. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) / С. B. Newman, M. Szarek, H. M. Colhoun et al. // Diab. Vase. Dis. Res. - 2008. - Vol. 5. - P. 177-183.
533. Time for new indications for statins? / M. Banach, D. P. Mikhailidis, S. E. Kjeldsen et al. // Med. Sci. Monit. - 2009. - Vol. 15. - P. MSI- MS5.
534. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction / A. C. Sposito, S. N. Santos, E. C. de Faria et al. // Coelho. Arterioscler. Thromb. Vase. Biol. - 2011. - Vol. 31 (5). - P.1240-1246.
535. TNF-a up-regulates protein level and cell surface expression of the leptin receptor by stimulating its export via a PKC-dependent mechanism / L. Gan, K. Guo, M. L. Cremona et al. // Endocrinology. - 2012. - Vol. 153. - P. 5821-5833.
536. Tobacco modalities used and outcome in patients with acute coronary syndrome: an observational report / J. Al Suwaidi, K. Al Habib, R. Singh et al. // Postgrad. Med. J. - 2012. - Vol. 88 (1044). - P. 566-574.
537. Tokuyama, Y., Osawa, H., Ishizuka, T. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus / Y. Tokuyama, H. Osawa, T. Ishizuka// Metabolism. - 2007. - Vol. 56 (5). - P. 693-698.
538. Tomkin, G. H. Atherosclerosis, diabetes and lipoproteins / G. H. Tomkin // Expert. Rev. Cardiovasc. Ther. - 2010. - Vol. 8 (7). - P. 1015-1029.
539. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women / C. Heidemann, Q. Sun, R. M. van Dam et al. // Ann. Intern. Med. - 2008. - Vol. 149 (5). - P. 307-316.
540. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice / G. M. Hirschfield, J. R. Gallimore, M. C. Kahan et al. // Proc. Natl. Acad. Sci U S A. - 2005. - Vol. 102. - P. 8309-8314.
541. Trayhum, P., Wood, I. S. Signalling role of adipose tissue: adipokines and inflammation in obesity / P. Trayhum, I. S. Wood // Biochemical Society Transactions. -2005.-Vol. 33 (5).-P. 1078-1081.
542. Treating to target patients with primary hyper! ipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) / H. J. Milionis, E. Rizos, M. Kostapanos et al. // Curr. Med. Res. Opin - 2006. - Vol. 22. - P. 1123-1131.
543. Tumor necrosis factor a inhibits signaling from the insulin receptor / G. S. Hotamisligil, D. L. Murray, L. N. Choy et al. // PNAS. - 1994. - Vol. 91. - P. 4854- 4858.
544. Tumor necrosis factor-alpha contributes to ischemia- and reperfusion- induced endothelial activation in isolated hearts / C. Kupatt, H. Habazettl, A. Goedecke et al. // Circ. Res. - 1999. - Vol. 4. - P. 392-400.
545. Two prospective studies found that elevated 2-hr glucose predictedmale mortality independent of fasting glucose and HbAlc / Q. Qiao, J. M. Dekker, F. de Vegt et al. // J. Clin. Epidemiol. - 2004. - Vol. 57. - P. 590-596.
546. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention / A. Badawi, A. Klip, P. Haddad et al. // Diabetes Metab. Syndr. Obes. - 2010. - Vol. 3. -P. 173-186.
547. Unger, R. H. Hyperleptinemia: protecting the heart from lipid overload / R. H. Unger // Hypertension. - 2005. - Vol. 45. -1031-1034.
548. Uysal, K. T., Wiesbrock, S. M., Hotamisligil, G. S. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-a - mediated insulin resistance in genetic obesity / К. T. Uysal, S. M. Wiesbrock, G. S. Hotamisligil // Endocrinology. - 1998. - Vol. 139. -P. 4832-4838.
549. VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes / W. Duckworth, C. Abraira, T. Moritz New England Journal of Medicine. - 2009. - Vol. 360 (2). - P. 129-139.
550. Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp / F. A. Moura, L. S. Carvalho, R. M. Cintra et al. // Am J Physiol Endocrinol Metab. - 2014. - Vol. 306 (4).-P. E399- E403.
551. Vaughan, D. E. PAI-I and atherothrombosis / D. E. Vaughan // J. Thromb. Haemost. - 2005. - Vol. 3 (8). -P. 1879-1883.
552. Verma, S., Yeh, E. T. C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation / S. Verma, E. T. Yeh // Am. J. Physio.I Regul. Integr. Comp. Physiol. - 2003. - Vol. 285. - P. R1253-R1256.
553. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women / J. W. Lee, J. A. Im, H. R. Lee et al. // Obesity. - 2007. - Vol. 15. - P. 2225-2232.
554. Von Willebrand factor and coronary heart disease: prospective study and meta-analysis / P. H. Whincup, J. Danesh, M. Walker et al. // Eur. Heart. J. - 2002. - Vol. 23.-P. 1764-1770.
555. Wallace, T. M., Levy, J. C., Matthews, D. R. Use and abuse of HOMA modeling / T. M. Wallace, J. C. Levy, D. R. Matthews // Diabetes Care. - 2004. - Vol. 27 (6).-P. 1487-1495.
556. Wallander, M., Soderberg, S., Norhammar, A. Leptin: a predictor of abnormal glucose toleranceand prognosis in patients with myocardial infarction and without previously known Type 2 diabetes / M. Wallander, S. Soderberg, A. Norhammar // Diabet Med. - 2008. - Vol. 25 (8). - P. 949-955.
557. Wanders, D., Plaisance, E. P., Judd, R. L. Pharmacological effects of lipidlowering drugs on circulating adipokines / D. Wanders, E. P. Plaisance, R. L. Judd // World J. Diabetes. -2010. - Vol. I. -P. 116-128.
558. Wang, B., Jenkins, J. R., Trayhum, P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-a / B. Wang, J. R. Jenkins, P. Trayhurn // Am J Physiol Endocrinol Metab. - 2005. - Vol. 288. - P. E731-E740.
559. Wang, Z., Hoy, W. E. C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians / Z. Wang, W. E. Hoy // Diabetes Res. Clin. Pract. - 2007.-Vol. 76(1).-P. 37-43.
560. Watts, G. F., Ooi, E. M. Balancing the cardiometabolic benefits and risks of statins / G. F. Watts, E. M. Ooi // Lancet. - 2012. - Vol. 380. - P. 541-543.
561. Woods, J. A., Vieira, V. J., Keylock, T. K. Exercise, Inflammation, and Innate Immunity / J. A. Woods, V. J. Vieira, T. K. Keylock // Neurologic Clinics. -
2006. - Vol. 24 (3). - P. 585-599.
562. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects // DoH. - 2008. - P. 1-5.
563. Yamagishi, S., Imaizumi, T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy / S. Yamagishi, T. Imaizumi // Curr. Pharm. Des. - 2005. - Vol. 11 (18). - P. 2279-2299.
564. Yang, R., Barouch, L. A. Leptin signaling and obesity. Cardiovascular consequences / R. Yang, L. A. Barouch // Circulation Research. - 2007. - Vol. 101. - P. 545-559.
565. Yeh, E. T. A new perspective on the biology of C-reactive protein / E. T. Yeh // Circulation Res. - 2005. - Vol. 97. - P. 609-611.
566. Yusuf, S. INTER-HEART: a study of risk factors for first myocardial infarction in 52 countries and over 27000 subjects / S. Yusuf // Paper presented at the European Society for Cardiology Congress. - 2004. - Munich, Germany. - URL: www.cardiosourse.com (10.11.2012).
567. Zaharan, N. L., Williams, D., Bennett, K. Statins and Risk of Treated Incident Diabetes in a Primary Care Population / N. L. Zaharan, D. Williams, K. Bennett//Br. J. Clin. Pharmacol. -2013. - Vol. 75(4). P. 1118-1124.
Еще по теме СПИСОК ЛИТЕРАТУРЫ:
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- Список литературы
- Список литературы
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- Список литературы
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- СПИСОК ЛИТЕРАТУРЫ
- Список литературы
- СПИСОК ЛИТЕРАТУРЫ